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ABSTRACT 
 
In Alzheimer’s disease, the possible correlation between abnormal deposition of proteins 
like hyperphosphorylated t and b-amyloid, cytoskeletal alterations and the deficit in the 
cholinergic neurotransmission remains to be clarified. In order to investigate the possible 
links connecting b-amyloid accumulation, t-hyperphosphorylation and nicotinic receptor 
expression, embryonic primary hippocampal cultures were incubated with amyloidogenic 
peptides. Ab1-42, the b-amyloid form with the highest fibrillogenic potential, was used for 
the experimental approach in this study. Additionally, a shorter form of the peptide, Ab31-34, 
was employed to investigate its putatively protective action against the impact of Ab1-42.   
Ab1-42 caused retraction of dendrites, shrinkage of cell bodies and a decrease in the total 
amount of MAP2b, without affecting the total number of neurons and their viability. No 
impact on the t-phosphorylation sites Ser-202 (antibody AT8), Thr-231 / Ser-235 (antibody 
AT180), Ser-262 (antibody 12E8) and Ser-396 / Ser-404 (antibody AD2) and on the 
expression of the a7-nAChR subunit protein was found. The total number of homomeric 
a7-nAChRs and their affinity for [125I]a-Bgt remained also unaltered. 
Upon Ab31-34 incubation cell bodies were swollen in the region of the apical dendrite. 
These morphological alterations, different from those elicited by Ab1-42, did not involve 
MAP2 expression changes. In contrast to Ab1-42, the shorter fragment caused a massive 
hyperphosphorylation of the t-protein at Ser-202 and at Ser-396 / Ser-404. The 
expression of the a7-nAChR subunit, the total number of homomeric a7-nAChRs and their 
affinity for [125I]a-Bgt were unaffected.  
As regards the colocalization of the receptor subunit with hyperphosphorylated t-protein, 
the a7-nAChR subunit was present in all AT8- and AD2-positive neurons under Ab31-34 
incubation. 
In conclusion, the present results show a toxic effect of Ab1-42 on the cytoskeletal structure 
at concentrations normally present in Alzheimer brains, but raise some doubts about the 
role of Ab1-42 fibrils as a direct trigger of t-hyperphosphorylation. As regards Ab31-34, it can 
not be considered protective with regard to cell morphology. Although it prevents the    
Ab1-42-induced retraction of dendrites, it shows own toxic properties. 
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1. INTRODUCTION 
  
1.1 Key features of Alzheimer’s disease 
 
Although in the last twenty years a plethora of knowledge about Alzheimer’s disease (AD) 
has been accumulated and an exponentially increasing amount of data has been 
produced, many crucial questions about its neuropathology remain open. The absence of 
early diagnostic tools and the lack of animal models, which have only recently become 
available, are the main problems that scientists have been facing in the investigation of 
the possible mechanisms leading to neuronal dysfunction in AD. 
Historically, the characterization of the disease had been based on post-mortem 
histopathological observations, which point to (1) extracellular deposition of b-amyloid 
(Ab) and (2) intracellular formation of neurofibrillary tangles (NFTs) as the hallmarks of the 
Alzheimer’s pathology (for review see Drouet et al., 2000).  
(1) Ab, generated by proteolytic cleavage of the ubiquitous expressed amyloid precursor 
protein (APP) (Kang et al., 1987), is the major constituent of mature plaques, in which it is 
surrounded by dystrophic neurites and infiltrates of reactive astrocytes and microglia 
(Busciglio et al., 1995). Ab is either directly toxic to cultured neurons or able to increase 
their vulnerability to excitatory neurotoxins (Koh et al., 1990; Mattson et al., 1993). Several 
groups agree that there is a strong correlation between the toxicity and the aggregation 
state of the peptide: the neurodegeneration seems in fact to require the formation of fibrils, 
while the amorphous aggregates would not be toxic (Arriagada et al., 1992; Lorenzo and 
Yankner, 1994; Busciglio et al., 1995; Lorenzo et al., 2000).  
(2) Neurofibrillary tangles are composed of self-aggregated hyperphosphorylated tau 
protein (t), a member of the group of the microtubule associated proteins (MAPs), and 
their spreading throughout the brain correlates with the severity of the disease (Grundke-
Iqbal et al., 1986).  
The identification of a precise sequence of events connecting Ab deposition and tangle 
formation would obviously play a key role in the understanding of the pathology, but 
nobody has so far provided such evidence, even though some studies have already 
shown the capability of Ab to induce and increase t-phosphorylation in cultured neurons 
(Takashima et al., 1993; Busciglio et al., 1995), and to accelerate the formation of 
neurofibrillary tangles (NFTs) when injected in transgenic mice expressing the P301L 
mutant human t-protein (Götz et al., 2001). 
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The most prominent clinical change in AD patients is a cognitive deficit caused most likely 
by the degeneration of cholinergic fibers arising from the forebrain and projecting to the 
cortex (Whitehouse et al., 1981; Rosser et al., 1982). Therefore many attempts have been 
made in order to restore the cholinergic activity in patients affected by the disease. At first 
the attention was focused on choline acetyltransferase (ChAT) and particularly on 
acetylcholinesterase (AChE), which are the enzymes responsible for acetylcholine (ACh) 
synthesis and breakdown, respectively. The treatment with cholinesterase inhibitors 
showed palliative effects on symptoms and some trend to slow the progression of the 
disease (Nordberg and Svensson, 1998; Giacobini, 2000; Van den Berg et al., 2000). 
Only later, as it was noticed that the administration of nicotine to experimental animals 
(Levin, 1992; Blondel et al., 2000; Grottick and Higgins, 2000) and to non-diseased 
human subjects (Wesnes and Warburton, 1983) improves attention and memory-related 
tasks,  nicotinic acetylcholine receptors (nAChRs) began to attract the interest of scientists 
as possible therapeutical targets (Newhouse et al., 1997; Lloyd et al., 1998; for review see 
Wevers and Schröder, 1999). It is therefore of great interest to understand if, and 
eventually how, Ab and hyperphosphorylated t-protein may influence the cholinergic 
system at the level of nAChRs.  
In this study attention will be focused on the effect of amyloidogenic peptides on t-protein 
phosphorylation state and on nAChR distribution and expression, in order to get new 
insights into possible correlations between these events. 
 
 
1.2 Neuronal nicotinic acetylcholine receptors (nAChRs) 
 
Transmitter-gated ion channels, like nAChRs, are transmembrane receptor proteins 
allowing the propagation of electric signals between nerve cells and their targets at the 
level of the chemical synapse. Neurotransmitters released from the nerve terminal interact 
with the ligand-binding domain of the receptor on the cell surface, thus triggering transient 
conformational changes in the structure that result in the opening of the gate in the 
membrane-spanning pore (for review see Sine, 2002). Although much information has 
been obtained about the relative positions of individual amino acids in the membrane-
spanning segments of nAChRs and about their roles in affecting ion transport, the first 
successful attempts to determine the detailed three-dimensional structure of the receptor 
and the conformational change mechanisms leading to the ion-influx have only recently 
been carried out (Miyazawa et al., 2003).  
 
      
                                                                                                                        1. Introduction 
                                                                      3  
  
 
1.2.1 Structure 
 
nAChRs belong to the superfamily of ligand-gated ion channels which includes g-amino-
butyric acid A (GABAA), glycine, and serotonin 3 (5-HT3) receptors. They exist as a 
variety of subtypes in the mammalian brain, formed as pentamers from different 
combinations of genetically distinct subunits. Nine distinct alpha subunits (a2-a10) and 
three beta (b2-b4) have been shown to assemble to a pentameric structure so far, but not 
all the possible combinations were found (Lustig et al., 2001; for reviews see Role, 1992; 
Sargent, 1993). Nucleotide and amino acid sequences are similar in all nAChR subunits: 
each subunit consists of an N-terminal extracellular domain, four transmembrane domains 
(M1-M4), with an extended intracellular loop between the third (M3) and the fourth (M4) of 
them, and of an extracellular C-terminal tail. The amino acid sequence of the 
cytoplasmatic loop represents the unique feature of the individual nAChR subunits, while 
the second transmembrane domain of every subunit forms the channel pore (for review 
see Lindstrom et al., 1995) (Fig.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1: Schematic view of a nicotinic acetylcholine receptor (nAChR). Five subunits, inserted 
into the membrane structure, form the channel complex (b). The neurotransmitter binding 
sites are located in the a -nAChR subunits. In (a), a single subunit with its N-terminal large 
hydrophilic domain, its four transmembrane domains and the loop is represented. 
 
The a7-nAChR subunit is the only subunit in the human central nervous system (CNS) 
able to form homomeric pentameric receptors, whereas the other subunits are always 
assembled in heteromeric combinations. Such a variety of nAChR subunits results in a 
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great diversity of functional nAChRs expressed throughout the CNS, which show distinct 
pharmacological and biophysical properties (for review see Albuquerque et al., 1997).   
There is strong evidence that transmembrane receptors are associated with lipid 
microdomains called lipid rafts, enriched in sphingolipids and cholesterol (Simons and 
Ikonen, 1997), which avoid the lateral diffusion of receptors in the membrane 
phospholipidic bilayer. nAChRs are also thought to be inserted in this environment, as 
already shown for the a7-nAChR subunit (Brusés et al., 2001). 
 
 
1.2.2 Cholinergic innervation, nAChR distribution and function 
 
The cholinergic system provides diffuse innervation to practically all parts of the brain and 
a small number of cholinergic nuclei send input to different brain areas (for reviews see 
Kasa, 1986; Woolf, 1991). Three major cholinergic projection subsystems can be 
identified. The first one arises from neurons in the pedunculopontine tegmentum and the 
laterodorsal pontine tegmentum and provides innervation to the thalamus, midbrain areas 
and also to the brain stem. The second one arises in the basal forebrain and sends 
projections mainly throughout the cortex, while the third one comes from the septum and 
innervates the hippocampus. A relatively low number of cholinergic neurons can in 
general give rise to projections reaching broad areas and can consequently influence a 
relatively high number of neuronal structures (for review see Dani, 2001). 
In neurons, nAChRs are located pre- and postsynaptically. Their prominent presynaptic 
role is to modulate the release of neurotransmitters - nAChRs are in fact able to increase 
the release of almost all examined neurotransmitters (McGehee et al., 1995; Gray et al., 
1996; Wonnacott, 1997; Li et al., 1998; Radcliffe et al., 1999) - while at the postsynaptic 
side they are responsible for direct excitation. Although the glutamatergic system is 
overwhelming in this way, nicotinic transmission can modulate the excitability of groups of 
neurons in different brain areas: besides their direct synaptic role, nAChRs can therefore 
influence neuronal circuits in a broader sense (for review see Dani, 2001). 
As regards the individual subunit composition, the a4b2 and a7 receptor subtypes are 
numerically the most abundant ones in the mammalian CNS (Lukas et al., 1999). Mapping 
studies indicate that nAChRs are present throughout the hippocampus (Perry et al., 
1993), which plays a central role in learning and memory, and in situ hybridization shows 
that the a7- and b2-nAChR subunits in particular are highly expressed in this area (Zarei 
et al., 1999).  
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When two molecules of ACh interact with their binding sites, located in the a-subunits of 
the receptor complex (Fig.1), the ion channel opens up for several milliseconds, allowing 
cations to enter the cell. The resulting ion influx can lead to a local depolarization of the 
membrane and produce an intracellular ionic signal. Sodium and potassium are the 
cations carrying most of the nAChR current, but calcium can also play a significant role. 
nAChR-mediated calcium entry can assume biological importance because it is different 
from the calcium influx through voltage-gated calcium channels or through the N-methyl-
D-aspartate (NMDA) subtype of glutamate receptors. Compared with the latter two, which 
require membrane depolarization to pass current freely, nAChR-mediated calcium influx 
can exhibit a different voltage dependence: nAChRs do function at negative potential, thus 
providing a strong voltage force driving cations into the cell. The distribution of the 
incoming calcium depends on the location of nAChRs on the cell surface (for review see 
Dani, 2001). 
 
 
1.2.3 nAChRs and Alzheimer’s disease 
 
The role of nAChRs becomes of main importance when considering the pathogenesis of 
the disease. Biological changes may lead to neurotransmitter release alterations and 
circuit excitability abnormalities (for review see Dani, 2001). In AD patients, 
measurements of the nAChR binding sites using nicotinic ligands have repeatedly shown 
a decrease in their number (Newhouse et al., 1997; for review see Wevers and Schröder, 
1999). The loss of binding sites in diseased brains was confirmed by autoradiography of 
[3H]nicotine, showing decreased binding in all cortical layers, particularly in the deepest 
ones (Nordberg and Winblad, 1986; Whitehouse et al., 1988). Looking at individual 
nAChR subunits, a remarkable decrease in the amount of a4-nAChR protein, analyzed by 
quantitative immunohistochemistry (Wevers et al., 2000) and Western blotting (Burghaus 
et al., 2000), has already been demonstrated by our group in the cerebral cortex of AD 
patients in comparison with age-matched controls, while the a7-nAChR protein shows a 
minor reduction. Although the most common type of central nervous nAChRs is 
represented by the association of the b2- with the a4-nAChR subunit, as previously 
mentioned (see 1.2.2), the level of the b2-nAChR subunit seems, in contrast to the a4-
nAChR findings, not to be altered (Guan et al., 2000). The fact that the nAChR mRNA 
distribution and the density of neurons expressing the nAChR transcripts in AD cortices 
did not show significant differences in comparison to controls suggests that the decrease 
in the number of nAChRs may be the result of post-translational events (Wevers et al., 
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1999; for review see Wevers and Schröder, 1999). Colocalization studies and in situ 
hybridization showed that the a4- and a7-nAChR subunit proteins and their transcripts 
exhibit a different behavior as to their histotopographical relation with regard to plaques 
and tangles: while both proteins and transcripts are still present in close vicinity or even 
inside of amyloid plaques, they disappear from almost all tangle-bearing neurons (Wevers 
et al., 1999; Wevers et al., 2001). 
 
 
1.3 b-amyloid  
 
1.3.1 b-amyloid formation  
 
Ab originates from the amyloid precursor protein (APP), which is a single transmembrane 
polypeptide. APP is expressed in a number of cell types, most notably in neurons, but its 
function remains unknown, although it is thought to be involved in many cellular 
mechanisms, including neurotrophic activity, synaptogenesis, modulation of neuronal 
excitability, protection against toxic insults and signal transduction functions. The 
extracellular N-terminal domain of APP represents the longest part of the structure, 
ranging between 590 and 680 amino acids, while the C-terminal cytoplasmatic domain 
has normally only 47 amino acid residues. Approximately one half of the Ab1-42 sequence 
lies extracellularly, while the other half, containing hydrophobic residues, lies within the 
phospholipidic bilayer. APP, during normal cellular metabolism, is processed by at least 
three different enzymes. These enzymes, indicated as a-, b- and g- secretases, cut the 
protein sequence at distinct positions. Ab1-42 is formed, together with Ab1-40, when g-
secretase APP-cleavage follows the b-cleavage, while the a-secretase pathway, cutting 
the Ab sequence in the middle, prevents its formation (for review see Mattson, 1997) 
(Fig.2). The g-secretase-mediated proteolytic cleavage of the APP C-terminal fragment 
seems to be influenced by presenilin-1 (PS1), a highly conserved transmembrane protein, 
point mutations of which are a major cause of familial Alzheimer’s disease (De Strooper et 
al., 1998). 
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Fig.2: a -, b- and g-secretase are the enzymes involved in APP cleavage. a-secretase cleaves 
the sequence at position 17 of the Ab fragment, which can, consequently, not be released in 
its entire form. The release of Ab1-40 and/or Ab1-42 occurs when the action of g-secretase, 
acting at position 40 and/or 42 of Ab, follows the b-secretase cleavage, which takes place at 
position 1 (Small and McLean, 1999). 
 
 
1.3.2 b-amyloid, neurodegeneration and Alzheimer’s disease 
 
Ab is cleared from the brain under normal conditions, but during aging, and to a much 
greater extent in AD, its propensity to form fibrils prevails. Several mechanisms can be 
involved in Ab toxicity. The peptide can not only suppress neuronal signaling by affecting 
receptor transduction and/or transmitter production, but also increase cell vulnerability to 
different metabolic and excitotoxic insults. In fact, in cell culture it has been demonstrated 
that the formation of Ab fibrils may be accompanied by generation of oxyradicals, 
membrane damage, impairment of membrane transport systems and disruption of ion 
homeostasis (for review see Mattson, 1997).  
As regards AD, some observations suggest that Ab, besides its role as a pathological 
hallmark (amyloid plaques), is directly involved in the neurodegenerative process.  
The first observation is that mutations of the APP gene on chromosome 21 may lead to 
AD, and that individuals carrying an extra copy of this chromosome due to trisomy 21 
(Down’s syndrome) present a higher number of plaques when compared with non-
diseased subjects if they live beyond their thirties. Furthermore, other early onset AD 
mutations, including presenilin-1 (PS1) and presenilin-2 (PS2), are associated with 
increased Ab production (Carter and Lippa, 2001). 
In comparison with the short-tailed Ab1-40, Ab1-42 is more neurotoxic, has a lower solubility 
and a greater tendency to form fibrils (Busciglio et al., 1995). Ab1-42 can also act as a 
 
 
  DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 
   N   C 
 b-secretase    a-secretase   g-secretase 
    1     31-34      40 42      
17 
Ab 
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“seed” for Ab1-40 fibril formation. Early diffuse amyloid plaques and age-related plaques in 
cognitively normal subjects are composed predominantly of Ab1-42 (Carter and Lippa, 
2001; for review see Mattson, 1997).  
A great number of Ab-related peptides have been studied to get hints about the 
mechanisms of amyloid cytotoxicity. Among these peptides, which exhibit different levels 
of toxicity, the synthetic peptide propionyl-IIGL (Pr-IIGL), an analogue of the region 31-34 
of Ab (see Fig.2), was in contrast reported to protect cultured astrocytes from Ab1-42-
induced changes in calcium metabolism (Laskay et al., 1997). 
 
 
1.3.3 b-amyloid and nAChRs 
 
Amyloid plaques, as already mentioned, are extracellular deposits. The extracellular 
accumulation of the peptide could, however, be a secondary step in the progression of 
events and follow its internalization, as recent studies have shown (Gouras et al., 2000). It 
has been hypothesized that the a7-nAChR subunit might play a fundamental role in the 
intracellular accumulation of Ab1-42 (Nagele et al., 2002). The first hints in this direction 
came from the high binding affinity of Ab1-42 for the receptor subunit (Wang et al., 2000). 
Subsequently, it was noticed that the internalization seems to take place particularly in 
those cells, like the pyramidal neurons, which are rich in the a7-nAChR subunit (Nagele et 
al., 2002). Moreover, it was demonstrated that cells transfected with the a7-nAChR 
subunit exhibit a lower viability after Ab incubation in comparison with their non-
transfected counterparts, and that a7-nAChR subunit inhibitors (e.g. a-bungarotoxin) 
prevent intracellular Ab accumulation (Nagele et al., 2002). By contrast, other authors 
reported a possible protective action of a7-nAChRs against Ab cytotoxicity, as selective 
antagonists of this receptor subtype reduce the protective effect of nicotine on 
Ab cytotoxic effects (Shimohama and Kihara, 2001). Although these findings are 
contradictory, they all suggest an interplay between the a7-nAChR subunit and Ab, which 
may represent a crucial step in the series of events leading to the Ab-induced cellular 
damage. A further investigation of this possible interaction is therefore required to extend 
the knowledge about the mechanisms of Ab cytotoxicity. 
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1.4 t-protein  
 
1.4.1 Structure and functions 
 
In the human brain, one single gene gives rise to six t-protein isoforms by alternative 
splicing. These isoforms, which range from 352 (fetal form) to 441 amino acids, differ in 
the presence of none, one or two 29 amino acid inserts encoded by exons 2 and 3 (the 
insert encoded by exon 3 is never present without the insert encoded by exon 2) in the N-
terminal domain, in combination with either 3 (R1, R3 and R4) or 4 (R1-R4) repeats in the 
C-terminal domain (R2 encoded by exon 10) (Fig.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3: Representation of the six t -protein isoforms expressed in the human brain, deriving 
from alternative splicing of a single gene (Buée et al., 2000). 
 
The C-terminal portion (repeats plus flanking regions) represents the “microtubule binding 
domain”, while the N-terminal portion of the protein is indicated as “projection domain” and 
determines the spacing between microtubules (Friedhoff et al., 2000; for review see Buée 
et al., 2000).  
As regards the amino acid composition, t-protein residues are mostly charged and 
hydrophilic and the protein displays a natively unfolded structure. t-protein, which is 
usually enriched in axons (Binder et al., 1985), normally stabilizes microtubules for their 
role in the development of cell processes, establishment of cell polarity and intracellular 
transport (Drewes et al., 1998).  
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1.4.2 t-protein and Alzheimer’s disease 
 
In AD, the normal balance between t-kinases and t-phosphatases seems to be disturbed 
and the phosphorylation state of the t-protein therefore abnormal (for reviews see 
Mandelkow et al., 1995; Trojanowski and Lee, 1995). t-protein distribution correlates with 
its phosphorylation state (Li and Black, 1996; Mandel and Banker, 1996) and in AD it 
mislocalizes from the axon to the somatodendritic compartment of neurons (Braak et al., 
1994). Hyperphosphorylated t-protein can in fact lose its capability to bind microtubules 
and aggregate into paired helical filaments (PHFs), which subsequently assemble to form 
NFTs. The phosphorylation at the C-terminal microtubule assembly domain seems to play 
an important role in this process. At least thirty phosphorylation sites have been described 
in the t-protein structure, mainly localized outside the microtubule binding domain. They 
can be broadly subdivided into two classes: several Ser-Pro or Thr-Pro motifs occur in 
both regions flanking the internal repeats and are targets of different enzymes (for review 
see Mandelkow and Mandelkow, 1998) (Fig.4). 
 
Fig.4: Phosphorylation sites are distributed along the entire structure of the t -protein. 
Different enzymes are responsible for the phosphorylation in different regions of the 
sequence (Mandelkow and Mandelkow, 1998). 
 
Mitogen activated protein kinase (MAPK), glycogen synthase kinase 3 (GSK-3), protein 
kinase A (PKA), t-tubulin kinase, Ca2+/calmodulin-dependent protein kinase type II 
(CaMKII) and cyclin-dependent kinases including cdc2 and cdk5 have been proven to be 
involved in the phosphorylation of the t-protein (Pei et al., 1998; Bennecib et al., 2001; for 
review see Buée et al., 2000). It has also been shown that distinct enzymes target 
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different t-phosphorylation sites. It is therefore very important to know at what sites the 
possible Ab-induced phosphorylation may be prominent in order to understand what 
mechanisms are responsible for this effect. So far, most studies in this field have been 
performed on brain slices. In the present study, the use of primary cultures will allow to 
investigate the involvement of these pathways at the cellular level.  
t-protein interacts not only with microtubules and other cytoskeletal elements, but also 
with the plasma membrane (Hirokawa et al., 1988; Brandt et al., 1995), where nAChRs 
are located. t-phosphorylation can modulate the properties of t-protein and influence its 
functions. Alterations of the t-protein phosphorylation state could therefore provoke 
changes at the membrane level, although it is still completely unknown whether this event 
may also have an impact on the nAChR subunit distribution within the phospholipidic 
bilayer. Moreover, cytoskeletal changes induced by t-hyperphosphorylation can affect the 
transport of vesicles and of organelles along the microtubules, leading to various 
problems, e.g. energy deficits and vulnerability against oxidative stress (Ebneth et al., 
1998; Trinczek et al., 1999; Stamer et al., 2002).  
 
 
1.5 Hippocampal primary cultures as a model for Alzheimer’s disease   
 
In this study, rat embryonic hippocampal neurons in low-density culture have been used 
as an in vitro model to study the expression of nAChRs and t-phosphorylation state under 
conditions which mimic certain aspects of AD.  
The hippocampus is a source of a rather homogeneous population of neurons with well-
characterized properties typical of CNS neurons in general (Goslin et al., 1998). 
Pyramidal-like neurons, the principal cell type in the hippocampus, have been estimated 
to account for 85% to 90% of the total neuronal population and they are similar to each 
other in many fundamental respects, even if they can differ from one another in some of 
their aspects (Goslin et al., 1998). In E18 to E19 fetal rats, from which our culture is 
prepared, the generation of pyramidal neurons is essentially complete, while the 
generation of dentate granule cells has scarcely begun (Schlessinger et al., 1978).  
An advantage of this model is that the low density facilitates the quantitative and 
morphological analysis (Goslin et al., 1998). Moreover, strong similarities between neurite 
dystrophy in AD and Ab1-42-induced neurite dystrophy in hippocampal neuronal cultures 
have been observed (Pike et al., 1992). On the other hand, a limitation in the study of AD 
is constituted by the fact that the formation of amyloid plaques from fibrillogenic Ab and 
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the aggregation of hyperphoshorylated t-protein into neurofibrillary tangles are long 
lasting processes which do not occur spontaneously in vitro and may require additional 
age-related factors not present in fetal cell cultures (Busciglio et al., 1995). The 
standardized experimental conditions mimic to some extent the first stages of the 
Alzheimer’s disease, where Ab fibrils start to aggregate but the formation of plaques has 
not begun (Busciglio et al., 1995). Using this model it is therefore possible to analyze 
selectively the impact of Ab and/or conditions leading to t-protein hyperphosphorylation 
on properties of the cytoskeleton and nAChR expression. 
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1.6 Aim of the project 
 
In Alzheimer’s disease, the possible correlation between abnormal deposition of proteins 
like  hyperphosphorylated t and b-amyloid, cytoskeletal alterations and the deficit in the 
cholinergic neurotransmission remains to be clarified. Incubation of embryonic primary 
hippocampal cultures with amyloidogenic peptides will allow for the investigation of 
possible links connecting b-amyloid accumulation, t-hyperphosphorylation and nicotinic 
receptor expression. Ab1-42, being the b-amyloid form with the highest fibrillogenic 
potential, will be used for the experimental approach in this study. Additionally, the shorter 
synthetic peptide propionyl-IIGL, analogue of the region 31-34 of Ab, will be employed in 
order to investigate its possible protective action against the impact of Ab1-42, as previously 
reported by studying Ab-induced calcium metabolism changes in cultured astrocytes 
(Laskay et al., 1997) and Ab-induced increase in the concentration of extracellular 
glutamate and aspartate in the magnocellular nucleus basalis of the rat (Harkany et al., 
1999). During this work, it will be referred to this peptide as Ab31-34.  
 
The following questions will be addressed in this study : 
 
1. Cytoskeletal structure and t-phosphorylation state 
a) Does the incubation with amyloidogenic peptides influence the neuron morphology 
and the neuronal cytoskeletal structure? 
b) Is there an increase in the level of t-phosphorylation at different phosphorylation 
sites after treatment and how is the abnormal phosphorylated t-protein distributed?  
 
2. nAChR  
a) Are the expression and compartmentalization of the single nAChR subunits altered 
by the presence of the two different Ab fragments? 
b) Are nAChR subunits affected by t-hyperphosphorylation?  
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2. MATERIALS AND METHODS 
 
 
2.1 Antibodies 
 
 
2.1.1 Primary antibodies 
 
a) to the cytoskeletal proteins 
                                                          source            manufacturer / reference 
•  monoclonal: AT8  mouse  Immunogenetics  
 Tau-1  mouse  Roche 
AD2  mouse  Dr. Delacourte, University of Lille,                                                        
France  (Buée-Scherrer  et al., 1996)          
AT180  mouse  Immunogenetics 
12E8  mouse            Dr. Seubert, Elan Pharmaceutical 
                                              Inc. San Francisco, USA  
                                              (Seubert et al., 1995)                    
MAP2  mouse  Sigma 
                               (clone HM2)    
                                           
                                        
b) to the nAChR subunits 
                                                          source            manufacturer / reference 
•  monoclonal :       a7-nAChR mouse  Dr. Lindstrom, University of  
                                (mAb306)    Pennsylvania, USA   
    (Dominguez del Toro et al., 1994)  
•  polyclonal:         a7-nAChR rabbit  Santa Cruz 
                                  (H-302) 
 
          b2-nAChR rabbit  Dr. Schütz, University  
       of Cologne (Schütz, 1999) 
                     a4-nAChR guinea pig Chemicon  
 
 
c) used as neuronal markers for: 
                                                          source            manufacturer / reference 
-pyramidal cells 
•  monoclonal :  SMI32  mouse  Sternberger  
 
-glutamatergic cells 
•  polyclonal :              VGLUT1        guinea pig       Chemicon  
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2.1.2 Secondary antibodies and markers 
                                                                                 source            manufacturer 
Anti-mouse IgG     goat    Dako 
Anti-rabbit IgG     goat   Dako 
Anti-guinea pig IgG        rabbit   Vector 
Anti-mouse IgG Cy2-conjugated   goat  Jackson 
Anti-rabbit IgG Cy3-conjugated   goat   Jackson 
Streptavidin Cy-3       Amersham 
Streptavidin-biotinylated horseradish    Amersham 
peroxidase complex  
 
  
2.2 Media and buffers 
 
2.2.1 Cell culture 
 
-PBS (10X) pH 7.4 
1.5 mM  KH2PO4 
1.5 M     NaCl  
2.7 M     Na2HPO4  
in distilled water 
 
-TBS pH 7.5 
50   mM  Tris  
150 mM  NaCl 
in distilled water 
 
-Isolation medium   
20 mM HEPES (2% v/v HEPES 1M)             GibcoTM, Invitrogen Corporation    
in Dulbecco’s modified Eagle Medium          GibcoTM, Invitrogen Corporation 
(with sodium pyruvate, 4.5 g/l glucose, pyridoxine)         
                                                                                                                                                             
-Culture medium  
1%         Glutamate            Sigma 
1%         Penicillin/Streptomycin             Gibco BRL, Life Technologies 
0.5 mM  Glutamine (0.25% v/v Glutamine 200mM)        Gibco BRL, Life Technologies                                                               
2%    B27 Supplement            Gibco BRL, Life Technologies 
in Neurobasal Medium (without L-glutamine)        GibcoTM, Invitrogen Corporation  
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2.2.2 Electrophoresis and Western blot 
 
-Electrophoresis buffer 
25 mM    Tris  
2.5 M      Glycine 
0.1%       SDS  
in distilled water 
 
-Transfer buffer  
25 mM     Tris      
150 mM   Glycine                 
20 %        Methanol                
in distilled water 
 
-Sample buffer  
 - SDS-mix solution :  1 ml  Tris 1M pH 6.8       
                                      4 ml  SDS 10%               
                                      5mg  Bromophenol Blue 
                                      2 ml  Glycerol                 
                                      1 ml  distilled water                      
 
- DTT 1M  
 
Sample buffer was prepared before use mixing DDT and SDS-mix (1:4) 
 
-Coomassie Blue 
0,1 g      Coomassie Blue 
100 ml   Methanol 
33 ml     Acetic acid 
distilled water to 200 ml 
 
 
2.3 Radioactive material 
 
(3-[125I]iodotyrosyl)a-Bungarotoxin        Amersham   
Specific activity: 5.5 TBq / mmol 
 
 
 
Chemical compounds were purchased from the companies Sigma, Merck, Promega, 
Pierce, Amersham and Serva. 
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2.4 Technical equipment 
 
2.4.1 Microscope 
 
To examine the immunocytochemical staining the Olympus Vanox AHBT3 photo-
microscope was used. The filter sets employed were “41007a filterblock for Cy2” and 
“41007a filterblock for Cy3” (AF-analysentechnik). The microscope is equipped with a 
DVC-1300 C RGB Color camera. Photos were taken using 40 x 2.5 magnification.  
 
 
2.4.2 C.A.S.T.-Grid system 
 
The Computer Assisted Stereological Toolbox (C.A.S.T.) is composed of a PC with 
installed stereology software (Olympus, Denmark), a SVHS video camera, a microscope 
equipped with a motorized specimen stage for automatic sampling, a multi-control unit for 
the control of the joystick movement (x- and y-axis ) and of the focus (z-axis). 
 
 
2.5 Cell culture 
 
2.5.1 Dissection of the hippocampus 
 
Brains of E18 to E19 Wistar fetal rats (local breeding) were collected in isolation buffer on 
ice (procedure conducted in accordance with the law for the prevention of cruelty to 
animals). Hippocampi were mechanically dissected from the brains (Fig.5) as described 
previously (Banker and Cowan, 1977; Goslin et al., 1998).   
 
 
2.5.2 Preparation of the cell suspension  
 
Hippocampi were collected in a 50 ml centrifuge tube containing isolation medium and 
maintained on ice. The medium was then poured off and the hippocampi treated with 5 ml 
0.05% trypsin-0.02% EDTA (GibcoTM, Invitrogen Corporation) for 15 min at 37°C under 
slight agitation and rotation (60 strokes/min) to allow the dissociation of the tissue. Trypsin 
was then discarded and the hippocampi washed three times with isolation medium. The 
resulting suspension (about 4 ml) was homogenized by gentle up-and-down pipetting 
using a long Pasteur pipette and its volume then filled to 35 ml with isolation medium. 
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Centrifugation at 1200 rpm for 8 min followed. The pellet was rinsed three times with 
isolation medium and re-homogenized as previously described. After filtration a 3 to 5 ml 
cell suspension was obtained. 
 
 
 
2.5.3 Cell plating 
 
The concentration of viable cells in the suspension was approximately determined by 
trypan blue exclusion. For this measurement, 50 ml of the suspension were incubated with 
50 ml of trypan blue (Sigma) for 5 min and cells were counted in a hemocytometer 
(Neubauer). The cell suspension was then diluted with an appropriate volume of culture 
medium before being plated on poly-L-lysine (Sigma, 10 mg/ml) precoated coverslips (for 
immunocytochemistry) or precoated culture dishes, in order to obtain a final density of 
approximately 4.75 x 104 cells / cm2. Each of the culture dishes (Ø 60 mm), where the 
coverslips were placed, contained 5 ml of suspension. Cells were grown in the incubator 
at 37°C. 
 
Fig.5: Dissection of the hippo-
campus. (A) Ventral view of the 
embryonic rat brain, with olfactory 
bulbs at the top. The dotted line 
indicates the approximate proje-
ction of the right hippocampus 
onto the surface. Arrowheads de-
marcate the junction between 
diencephalon and cerebral hemi-
sphere, along which the first cut is 
made (B) to separate the two 
parts. (C) Meninges are removed 
and in (D) the two edges of the 
hippocampal structure are clearly 
recognizable. Using fine scissors 
it is possible to cut around the 
margin (E) and remove completely 
the hippocampus (F). (Goslin et 
al., 1998) 
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Fig.6: Formation of Ab1-42 fibrils  
after pre-aging was confirmed 
by electron microscopy (nega-
tive staining) using a Zeiss EM 
902. Magnification x20000. 
2.5.4 Medium change 
 
After three days, 50% of the culture medium was replaced with fresh medium lacking 
glutamate. Three days later a 100% medium change was performed. 
 
 
2.5.5 Incubation 
 
One day after the 100% medium change (culture day 7), hippocampal neurons were 
incubated with vehicle or with aqueous solutions of Ab1-42 (Bachem) and Ab31-34 (Dr. 
Penke, University of Szeged, Hungary) at a final concentration of 0.5 mM and 0.125 mM, 
respectively. Aliquots of Ab1-42 (350 mM) were pre-aged at 37°C for 4 days to allow the 
formation of fibrils (Fig.6), as previously described (Lorenzo and Yankner, 1994). Ab31-34 
was not pre-aggregated (Laskay et al., 1997).  
 
 
 
 
 
 
 
 
 
 
2.5.6 Fixation 
 
After three days of treatment (culture day 10) the supernatant was removed (and collected 
for the cytotoxicity assay) and cells were washed 3 times with phosphate buffered saline 
(PBS), 37°C, pH 7.4. They were then fixed with 4% paraformaldehyde - 4% sucrose in 
PBS, pH 7.4, for 15 min at 37°C. A 3-times washing with PBS followed. Cells were stored 
in a moist chamber at 4°C.  
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2.6 Cytotoxicity assay 
 
The measurement was performed employing the CytoTox® non-radioactive assay 
(Promega), a colorimetric quantitative determination of lactate dehydrogenase (LDH), in 
the cell culture supernatant. According to the manufacturer’s protocol, 12 ml of room 
temperature assay buffer were added to one bottle of substrate mix. In a 96-well assay 
plate, 50 ml of the tetrazolium salt (INT) containing reconstituted substrate mix were added 
in each well to 50 ml of supernatant, collected from differently treated cultures. Every 
sample (Ab1-42 0.5 mM, Ab31-34 0.125 mM, Ab1-42 + Ab31-34 and vehicle), as well as the LDH 
positive control, were measured in quadruplicate. Culture medium was taken as blank for 
the absorbance values. After 30 min at room temperature the reaction converting 
tetrazolium into a red formazan product was stopped by 50 ml of stop solution (acetic acid 
1M) and the absorbance read at 490 nm in a ELISA reader within 1h. The amount of color 
formed is proportional to the number of lysed cells. 
 
                                                         LDH 
                       NAD+  +  lactate                          pyruvate  + NADH 
 
                                                    Diaphorase 
                       NADH  +  INT                          NAD+  + formazan (red)  
 
 
Additionally, further vehicle-treated probes were incubated with lysis solution (Promega) 
for 45 min before the supernatant was collected, in order to determine the maximum of 
absorbance (all cells are lysed) and correlate it to the values measured for the samples. 
 
  
2.7 Immunocytochemistry 
 
2.7.1 Immunoperoxidase staining 
 
Immunocytochemistry was performed by means of the avidin-biotin-peroxidase complex 
(ABC) method. Cells were permeabilized using 0.2% Triton X-100 in PBS (20 min, RT) 
and subsequently incubated - with washes in PBS (3x5 min each) after each step - for 15 
min in a 2% hydrogen peroxide solution in PBS.  Cells were blocked for 1h in 10% normal 
rat serum in 1% BSA/PBS and the primary monoclonal antibody MAP2 (1:1000 in 1% 
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BSA/PBS) applied overnight at 4°C. After reblocking with 5% normal goat serum solution 
in 1% BSA/PBS for 1h, cultures were incubated in biotinylated secondary antibody goat 
anti-mouse IgG (1:200) in 1% BSA/PBS. Finally, a 40 min streptavidin-peroxidase 
complex (1:200 in 1% BSA/PBS) (Amersham) treatment followed. The final staining was 
achieved by using diaminobenzidine tetrahydrochloride (DAB) fortified with a glucose 
oxidase-nickel sulfate peroxidase substrate (5-10 min). Controls performed by omission of 
the primary antibody during the corresponding incubation gave negative results. All 
coverslips were mounted on glass slides using Entellan® (Merck). 
 
 
2.7.2 Immunofluorescence 
 
Following fixation, cells were washed 3 times with PBS and membranes permeabilized 
with 0.2% Triton X-100 in PBS for 20 min at RT. In the case of the b2-nAChR subunit this 
step was omitted, because the epitope recognized by the b2-nAChR antibody is known to 
be extracellular (Schütz, 1999). Washing with PBS (3x5 min each) followed each step of 
the procedure. After blocking with 10% BSA/PBS for 1h, cells were incubated with primary 
polyclonal antibodies directed to the a7-nAChR subunit (H-302, 1:250), b2-nAChR 
subunit (1:200), a4-nAChR subunit (1:400) or VGLUT1 (1:5000) in 1% BSA/PBS 
overnight at 4°C. Blocking with 5% normal goat serum in 1% BSA/PBS for 30 min followed 
and Cy3-conjugated goat anti-rabbit IgG (1:1000 in 1% BSA/PBS) or biotinylated goat 
anti-guinea pig IgG (1:400) plus Streptavidin-Cy3 (1:500) were used as fluorescent 
secondary antibodies (40 min). Cells were then blocked again with 5% BSA/PBS for 1h 
and incubated with one of the primary mouse monoclonal antibodies (mAb) MAP2 (1:500), 
SMI32 (1:800), a7-nAChR 306 (1:350), or with the t-protein phosphorylation sites specific 
antibodies AT8 (Ser202) (1:1000), AD2 (Ser396 / Ser404) (1:10000), AT180 (Thr231 / 
Ser235) (1:400) and 12E8 (Ser262) (1:100) in 1% BSA/PBS overnight at 4°C. Blocking 
with 5% normal goat serum solution in 1% BSA/PBS for 1h and treatment with the 
secondary antibody Cy2-conjugated goat anti-mouse IgG (1:500) followed (40 min). 
Coverslips were mounted on glass slides using Entellan® (Merck). 
 
2.7.3 Assessment of neuron numbers 
 
The unbiased stereology-based estimation of total neuron numbers was performed using 
the 2D fractionator (Gundersen, 1986; Gundersen et al., 1988) in conjunction with the 
C.A.S.T.-Grid system,  which allows systematic uniform random sampling using a soft-
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ware-controllable microscope stage. At least three specimens were evaluated for each of 
the incubation conditions (Ab1-42 0.5 mM, Ab31-34 0.125 mM, Ab1-42 + Ab31-34 and vehicle). 
Means of the individual counting results were used for further statistical evaluation. The 
sampling area (113.3 ± 2.0 mm2) was delineated manually at 1.25x magnification using a 
mouse-driven cursor, the margin of the coverslip representing the boundary. 
The distance between the counting frames (frame area: 6344 mm2, corrected for 
magnification) was 800 mm in both the x and the y directions. The number of counting 
frames was calculated by a sub-routine in the C.A.S.T system and automatically 
superimposed on the video overlay. The 2D unbiased counting frame was displayed on 
the computer screen taking up 25% of the screen area. Counting of the neurons (40x oil 
immersion objective) was initiated at a random position, continued by moving the 
computer-controlled microscope stage holder stepwise in a meandering pattern over the 
entire section. All immunolabeled and morphologically intact-appearing neurons sampled 
were counted. The total number of neurons on the coverslip was obtained using the 
following formula (Ventimiglia et al., 1995):     
 
N = åQN * (dx * dy / AFRAME) 
 = åQN * (800 mm * 800 mm / 6344 mm2) 
where åQN  is the sum of the neurons counted, dx and dy are the sampling steps (mm) 
in the x or y direction, respectively, and AFRAME is the area of the counting frame corrected 
for magnification (mm2) (Schröder et al., 2004).  
 
 
2.7.4 Immunoreactive area measurement 
 
This measurement was also performed using the C.A.S.T.-Grid system. The set-up was 
the same described in 2.7.3. A system-connected software allowed the estimation of the 
total stained surface appearing on the screen for every randomly-selected frame inside 
the delineated sample area. Five specimens were evaluated for each of the incubation 
conditions (Ab1-42 0.5 mM, Ab31-34 0.125 mM, Ab1-42 + Ab31-34 and vehicle). Means of the 
individual measurement results were used for further statistical evaluation. The 
immunoreactive area was expressed as percent of the total analyzed area on the 
coverslip using the following formula: 
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% immunoreactive area     =    (  åAs   /   åATOT  )    x    100                    
                
where  åAs  is the total stained area measured and åATOT is the total analyzed area. 
 
 
2.8 Cell extract 
 
After having undergone one of the various treatments described above, cells were 
washed in PBS (pH 7.4) and harvested from the culture dish scraping them directly in lysis 
buffer (1% Triton X-100 in PBS, 0.1 mM PMSF, 1% v/v protease inhibitors cocktail P 2714 
stock solution [Sigma]) and the resulting suspension stirred at 4°C for 30 min. After a short 
sonication, the suspension was centrifuged at 10000 rpm for 10 min and an aliquot of the 
supernatant was used to determine the total protein concentration. The supernatant was 
then mixed 1:3 with electrophoresis sample buffer, boiled for 5 min and used for Western 
blot analysis.  
 
 
2.9 Protein estimation 
 
For the estimation of the total protein concentration in the samples the bicinchoninic acid 
method (BCA kit, Pierce) was applied. This colorimetric assay, in which Cu2+ ions are 
reduced to Cu+ and form a violet-colored complex with bicinchoninic acid (Wiechelman et 
al., 1988), was chosen for its resistance against detergents like Triton X-100. The use of 
such detergents in the lysis buffer was in fact necessary for the extraction of membrane 
proteins (Rehm, 2000). Concentrations of 0.2, 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 mg/ml of BSA 
in lysis buffer were used to obtain the standard curve. 200 ml of a 1:50 solution of reagent 
A and B (BioRad) were added to 25 ml of each probe or standard solution pro well. 25 ml 
of buffer were used for the blank. The probes were then kept at 37°C for 30 min and 
subsequently 10 min at RT. The measurement of the protein concentration was performed 
using an ELISA reader at 570 nm. 
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2.10 Electrophoresis 
 
Identical amounts (15-150 mg) of differently treated samples were loaded on each lane 
and run on SDS-page (10% or 4-15%) at constant voltage (100v) in a Mini-PROTEAN® 3 
Cell system (BioRad). Pre-stained protein molecular mass standards (Bio-Rad) were 
included in the same gel.        
 
 
2.11 Western blot 
 
Gels and membranes were equilibrated for 15 min in transfer buffer and proteins 
subsequently transferred onto the nitrocellulose membranes using a tank blotting system 
(BioRad). Gels were then treated with Coomassie Blue and decolorized with 8% methanol 
and 7% acetic acid to examine the quality of the electrophoretic separation. Membranes 
were stained with Ponceau S (Sigma) to verify the protein transfer and blocked with TTBS 
(0.1% Tween 20 in TBS) containing 5% milk powder for 1h. Incubation with antibodies 
against the t-phosphorylation sites AT8 (1:2000), AT180 (1:2000), Tau-1 (1:4000), AD2 
(1:5000), 12E8 (1:2000) and antibodies against the a7- (306, 1:500) and a4-subunit 
(1:1000) of the nAChR in TTBS containing 1%-5% milk powder overnight at 4°C followed. 
The biotinylated secondary antibodies anti-mouse IgG (1:5000) and anti-guinea pig (for 
the a4-nAChR subunit) in 1%-5% milk powder/TTBS were used. After streptavidin-
peroxidase treatment (1:5000-1:10000 in 5% milk powder/TTBS), immunodetection was 
performed using chemiluminescence reagents (Pierce). Immunoreactive bands were 
quantified with the Kodak Image Station 440. 
 
 
2.12 Receptor binding assay 
 
The binding capability of the homomeric a7-nAChRs was measured using [125I] a-
bungarotoxin ([125I] a-Bgt). Cultures were incubated with (for non-specific binding) or 
without (for total binding) 100 nM cold a-Bgt (Sigma) in 500 ml culture buffer at 37°C for 
30 min. Probes were then treated with different concentrations of the radioligand (0.039-
39 nmol/l) for 1 h at RT. Three samples were incubated with each concentration. After 
treatment, coverslips were washed twice with cold PBS, dried, and the radioactivity 
measured using an Isomed 200 counter. The values obtained were then referred to the 
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average amount of protein present on the coverslip under each incubation condition, 
determined on separate culture samples.  
 
 
2.13 Data bank search 
 
The search for proteins containing the tetrapeptidic sequence of Ab31-34 (IIGL) was 
performed using the BLAST program (Basic Local Alignment Search Tool) form Expasy 
(www.expasy.org) and restricted to human proteins. 
 
 
2.14 Statistical evaluation  
 
For neuron number assessment, total MAP2-stained area mesuarement, cytotoxicity 
assay, Western blot analysis and binding assay, the determination of the statistical 
significance was performed employing the two-tailed paired Student’s T-test. In the 
Western blot analysis and binding assay, the mean of three independent measurements 
of each sample was used for further statistical analysis.  
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3. RESULTS 
 
3.1 Neuron labeling in cell culture 
 
In order to investigate the general cell morphology in the hippocampal primary cultures - 
used as a model system in this study - neurons were immunostained with a MAP2 
monoclonal antibody. This is an antibody directed against a group of microtubule-
associated proteins (MAPs) and represents a specific marker for neurons. MAP2 proteins 
are in fact the neuronal MAPs, present only in trace amounts in non-neuronal cells. MAP2 
proteins are preferentially localized in the dendrites of mature neurons (Dotti et al., 1988) 
and they are fundamental for microtubule polymerization (for review see Buée et al., 
2000). The prevalent localization of MAP2 proteins in the somatodendritic compartment of 
hippocampal pyramidal cells is found not only in brain tissue sections, but also in 
hippocampal neurons which develop in culture, even if they grow at very low density 
without contacting neighboring cells (Caceres et al., 1984). MAP2 immunocytochemistry 
intensely stains the dendritic processes, including their finest branches, thus providing an 
overview of the dendritic tree in its full extension. The MAP2 staining can therefore give 
information about dendritic development, dendritic morphology in culture and possible 
changes in the cytoskeletal structure of neurons (Caceres et al., 1984; Busciglio et al., 
1992). As expected, MAP2-positive cells in our cultures were labeled in the 
somatodendritic compartment and along the dendrites (Fig.7a). As reported in chapter 
1.5, the “pyramidal-like” neurons in the culture should represent 85% to 90% of the total 
neuronal population (Goslin et al., 1998). In order to characterize these neurons, cultures 
were incubated with SMI32, an antibody against neurofilament proteins, which was shown 
to label a subset of pyramidal neurons in human and monkey neocortex (Campbell and 
Morrison, 1989) (Fig.7b). The immunolabeling obtained did not allow to differentiate 
between cells, as all of them were stained. Another attempt was made by using an 
antibody against the vesicular glutamate transporter 1 (VGLUT1). Glutamate is 
considered to be the main neurotransmitter of neocortical and hippocampal neurons 
(Francis et al., 2003) and VGLUT1 was found to be present in a subgroup of 
glutamatergic neurons (Bellocchio et al., 2000). Also in this case all cells were labeled 
(Fig.7c) (non-neuronal cultures were also used to check for unspecific binding and no 
staining was obtained with the two antibodies, data not shown). Under these culture 
conditions it seems therefore not possible to characterize neurons on the basis of their 
SMI32 or VGLUT1 immunoreactivity. 
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Fig.7: MAP2 staining in untreated cultures (a). Cell bodies and dendrites were intensely 
immunoreactive. When labeled with the antibodies SMI32 (b) or VGLUT1 (c), all neurons 
resulted to be stained. Bars: 50 mm [(a) and (b)]; 20 mm (c). 
 
 
3.2 a7- and b2-nAChR subunit immunoreactivity in cultured neurons 
 
All MAP2-positive neurons displayed a7-nAChR immunoreactivity, indicating that this 
subunit is expressed by all neurons in our cultures (Fig.8a,8b). b2-nAChR subunit 
immunoreactivity was also present in most neurons, but it seemed to be located in 
different cell compartments when compared to the a7-nAChR subunit labeling. The latter 
was more homogeneously distributed on the cell surface, while the b2-nAChR subunit 
exhibited an intermittent immunostaining in the perikarya and along the dendrites (Fig.8d). 
The peculiar pattern of the b2-nAChR subunit labeling did not allow to make precise 
considerations about the neuron morphology. In the present study, a neuron was 
considered “healthy” when the cell body was completely stained and it had multiple 
dendrites. In the case of the b2-nAChR subunit it would be impossible to determine if a 
given cell is only partially stained because it is damaged or because of the characteristic 
staining. For this reason it was decided not to proceed with further investigations of the 
b2-nAChR subunit. 
Immunochemical staining was performed also for the a4-nAChR subunit, but the Western 
blot analysis raised some doubts about the specificity of the antibody used (see Results: 
appendix). 
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  (c)      (d) 
 
Fig.8: nAChR subunit labeling in rat hippocampal primary cultures. The a7-nAChR staining 
(b) was homogeneously distributed on the cell surface, while only parts of the perikarya and 
of the dendrites were intensely labeled in neurons stained for the b2-nAChR subunit (d). For 
both subunits, the correspondent MAP2 staining is shown on the left-hand side (a,c). In (d), 
the inset is the enlargement of the area inside the dotted frame. Arrows indicate the 
intermittent labeling. Bars: 50 mm [(a), (b), (c) and (d)]; 20 mm [inset (d)]. 
 
 
3.3 Effect of Ab 1-42 on cultured neurons   
 
3.3.1 Neuron morphology and number 
 
As can be seen in Fig.9, incubation with a 0.5 mM? aqueous solution of pre-aged Ab1-42 
resulted in retraction of the dendrites and shrinkage of the cell bodies in MAP2-
immunoreactive (MAP2-ir) neurons. Morphologically altered neurons did not lose their 
MAP2 immunoreactivity: cell counting showed that the number of MAP2-positive neurons 
per coverslip was not significantly different when comparing treated cells with controls 
(Fig.10), immunoperoxidase staining and immunofluorescence yielding the same results. 
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Fig.9: MAP2 immunoreactivity in Ab1-42-treated cells. Many neurons were shrunken and had 
shorter or no dendrites (arrows). [Ab1-42] = 0.5 mM. Bar: 50 mm. 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.10: Total number of MAP2-positive cells in controls (£ ) and Ab1-42-treated cultures (¢ ) 
(n=5; results are expressed as mean ± SEM; P>0.05). [Ab1-42] = 0.5 mM. 
       Sample   MAP2-positive cells 
      per coverslip  
        Control       21508  ±   904 
        Ab1-42       21448  ±  1062 
MAP2 
 
Ab1-42 
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3.3.2 LDH determination 
 
To get information about neuron viability the LDH release in the culture supernatant was 
measured, as it is proportional to the number of lysed cells. This technique allows fast and 
simple cytotoxicity measurements (Korzeniewski and Callewaert, 1983). The results 
obtained in controls were not significantly different from those obtained in incubated 
cultures (Fig.11). The presently used concentration of Ab1-42 seems therefore to cause 
cellular damage, as shown by MAP2 immunoreactivity, without affecting the neuron 
viability.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.11: Cytotoxicity measurement in controls (£ ) and Ab1-42-treated cultures (¢ ), reported 
as formazan absorbance (n=4; results are expressed as mean ± SEM; P>0.05). [Ab1-42] = 0.5 
mM. 
 
 
       Sample Absorbance (490 nm) 
        Control          0.15  ±  0.03 
        Ab1-42          0.19  ±  0.06 
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In order to determine the percentage of lysed cells normally present in the samples, 
vehicle treated cultures were incubated with a lysis solution (Promega). Under this 
treatment all cells should be lysed and the LDH release therefore correspond to the 
maximum LDH release. Comparing this value with the LDH release of vehicle-treated 
cultures not incubated with lysis solution, it turned out that the lysed cells in the samples 
represent about 13.12 ± 1.16 % of the total population (n=3; result expressed as mean ± 
SEM). 
 
3.3.3 Morphological measurements 
 
The Ab-induced morphological changes observed with immunocytochemistry (dendrite 
retraction and cell body shrinkage) were quantified measuring the total MAP2-stained 
area on the coverslip with and without Ab1-42 treatment. As can be seen in Fig.12, there 
was a statistically significant difference in the MAP2-ir area between controls and Ab1-42-
treated cultures. This finding is in accordance with the morphological alterations described 
in 3.3.1. As the total number of MAP2-positive cells was not affected after incubation, it 
can be assumed that a decrease in the total MAP2-labeled area only depends on the 
observed retraction of the dendrites and shrinkage of the cell bodies. For this 
determination immunoperoxidase labeling was used, because it allows a more precise 
staining of the processes and because the contrast can be better appreciated by the 
computer system.   
 
3.3.4 Quantitative determination of MAP2 isoforms 
 
The term MAP2 refers to three different proteins which are derived from a single gene and 
have a similar amino acid sequence. MAP2a and MAP2b are the high molecular weight 
isoforms (280 kD and 270 kD, respectively), while MAP2c represents a shorter form 
(70kD). MAP2b, which is composed of 1830 amino acids, is the only isoform expressed 
throughout life in rat brain and it is involved in neurite outgrowth, during which its level 
remains fairly constant. MAP2c, which is made up of 467 amino acids, lacks the projection 
domain that stabilizes microtubules and it is believed to maintain the cytoskeleton in a 
more flexible state during development (for review see Shafit-Zagardo and Kalcheva, 
1998). MAP2c can be found in many brain areas only before P10, while MAP2a appears 
after P10 and seems to replace MAP2c in mature neurons. This developmental switch 
occurs during maturation of neuronal processes and it is thought to be related to the 
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growth of dendrites and their increasing thickness in this phase (for reviews see Goedert 
et al., 1991; Shafit-Zagardo and Kalcheva, 1998). Compared to vehicle-incubated cultures 
- the values of which were scaled to 100% - incubation with Ab1-42 led to a significantly 
decreased amount of MAP2b, while the amount of MAP2c (fetal form) was not altered 
(Fig.13).  
 
 
 
 
Fig.12: The MAP2-stained area was measured as percent of the total area on the coverslip in 
controls (£ ) and Ab1-42-treated cultures (¢ ) (n=5; results are expressed as mean ± SEM; 
*P<0.05). [Ab1-42] = 0.5 mM. 
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       Sample                MAP2c             MAP2b 
        Control                  100                100 
        Ab1-42            93.3 ± 4.3         63.7  ±  8.7 
              Control  Ab 1-42 
- 270 KD 
  (MAP2b) 
 
 
 
-  70 KD 
  (MAP2c) 
 
Fig.13: Western blot analysis 
of the two MAP2 isoforms (a). 
The total amount of MAP2b 
resulted to be significantly re-
duced under Ab1-42 incubation 
(¢ ) in comparison to controls 
(£ ), while MAP2c remained 
unaltered (b) (n=5; results are 
expressed as percent of 
controls and represent the 
mean ± SEM; *P<0.05). [Ab1-42] 
= 0.5 mM. 
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3.4 Effect of Ab 1-42 on the phosphorylation state of the t-protein 
 
Among the different phosphorylation sites of the t-protein, attention was focused on four 
of them, situated in different functional domains of the structure. The antibodies AT8 
(Ser202), AT180 (Thr231 / Ser235), 12E8 (Ser262) and AD2 (Ser396 / Ser404) were used 
in this study. AT8 is the most commonly used antibody to detect t-hyperphosphorylation 
in AD brains (Braak and Braak, 1995). AD2 detects t-phosphorylation in the protein 
segment probably involved in the formation of paired helical filaments (PHFs) and is 
therefore highly interesting (Buée-Scherrer et al., 1996). AT180 sites are located in the 
proline-rich region flanking the microtubule binding domain, while the 12E8 site is located 
within the microtubule binding domain and its phosphorylation might lead to the 
dissociation of the t-protein from the whole microtubule structure (for review see 
Mandelkow and Mandelkow, 1998).  
 
3.4.1 Immunocytochemistry 
 
The immunoreactivity pattern obtained with the antibodies directed to the different           
t-protein phosphorylation sites did not show any difference after incubation. Ab1-42- and 
vehicle-treated cells seemed to display the same level of immunoreactivity when labeled 
with AT8 (Fig.14), AD2 and 12E8 (Fig.15), while the signal obtained with AT180 was weak 
in both cases and it was hardly possible to distinguish the immunoreactivity from the 
background (Fig.15). In order to check these observations quantitatively, numbers of  
AT8-, AD2- and 12E8-ir neurons were assessed. No significant differences between 
vehicle- and Ab1-42-treated cultures were found (Fig.16).  
Fig.14: Immunostaining of phosphorylated t -protein using AT8 antibody in controls (a) and 
Ab1-42-treated cultures (b). [Ab1-42] = 0.5 mM. Bar: 50 mm. 
  control Ab1-42
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Fig.15: Immunofluorescence labeling of different t -phosphorylation sites was performed 
using AD2 (a,b), 12E8 (c,d) and AT180 (e,f) antibodies in controls (left-hand side) and Ab1-42-
treated cultures (right-hand side). [Ab1-42] = 0.5 mM. Bar: 50mm. 
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       Sample      AT8-positive cells 
           per coverslip 
        Control          7230  ±  828  
        Ab1-42          7364  ±  477 
       Sample      AD2-positive cells 
           per coverslip 
        Control          4775  ±  338  
        Ab1-42          4473  ±  168 
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Fig.16: Total number of AT8- (a), AD2- (b) and 12E8-ir neurons (c) in controls (£ ) and Ab1-42-
treated cultures (¢ ) (n=3; results are expressed as mean ± SEM; P>0.05). [Ab1-42] = 0.5 mM. 
 
 
The detection of phosphorylated t-protein in untreated cells was not surprising, as the 
fetal form of the protein normally exhibits higher levels of phosphorylation in comparison 
to the adult forms (Goedert et al., 1993; Watanabe et al., 1993). 
 
 
 
 
 
 
 
 
 
 
 
       Sample     12E8-positive cells 
           per coverslip 
        Control          7314  ±  700  
        Ab1-42          6456  ±  1071 
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3.4.2 Western blot analysis 
 
In order to complete the data obtained with cell counting, quantitative measurements of 
the total amount of phosphorylated t-protein at the considered sites were performed. Also 
in this case, a certain level of phosphorylation, typical of the fetal t-protein, was detected 
in untreated samples. No significant increase of phosphorylated t-protein at AT8 sites 
occured after Ab1-42 incubation (Fig.17). Membranes were also incubated with the 
antibody tau-1, directed against t-protein dephosphorylated at Ser199 / Ser202 (AT8 site). 
As expected, there was no significant reduction in the concentration of this protein, 
confirming that the considered epitopes are not hyperphosphorylated under these 
incubation conditions (Fig.18).  
 
 
 
 
 
 
Fig.17: Total amount of t -protein phosphorylated at AT8 epitopes. The bands obtained by 
Western blot analysis from controls (£ ) and Ab1-42-treated cultures (¢ ) were quantified 
using a densitometer (n=5; results are expressed as percent of controls and represent the 
mean ± SEM; P>0.05). [Ab1-42] = 0.5 mM. 
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Fig.18: Densitometric analysis of the total amount of t -protein dephosphorylated at tau-1 
epitopes revealed no stati stically significant alteration in the expression of the protein in 
Ab1-42-treated cultures (¢ ) in comparison to controls (£ ) (n=6; results are expressed as 
percent of controls and represent the mean ± SEM; P>0.05). [Ab1-42] = 0.5 mM. 
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The results obtained using AT180 (Fig.19), AD2 and 12E8 antibodies (Fig.20) pointed in 
the same direction, suggesting that Ab1-42 does not play a role as a t-hyperphos-
phorylating agent at the concentrations currently used.  
 
 
 
 
 
 
 
Fig.19: Western blot analysis of t -protein phosphorylated at AT180 epitopes. In controls (£ ) 
and Ab1-42-treated cultures (¢ ) the amount of phosphorylated protein was not significantly 
different, as shown by quantitative measurements (n=5; results are expressed as percent of 
controls and represent the mean ± SEM; P>0.05). [Ab1-42] = 0.5 mM. 
 
 
 
 
 
 
 
 
 
 
 
 
       Sample              AT180         
        Control                 100  
        Ab1-42        115.3  ±  7.7 
 Control  Ab 1-42 
- 50 kD 
AT180 
Western blot analysis
0
20
40
60
80
100
120
140
Control                   Ab 1-42
%
 o
f c
on
tr
ol
                                                                                                                               3. Results 
                                                                      41  
(b) 
 
 
 
 
 
 
 
 
Fig.20: Western blot analysis of t -protein phosphorylated at AD2 (a) and 12E8 epitope s (b). 
In Ab1-42-treated cultures (¢ ) the amount of phosphorylated protein was not significantly 
changed in comparison to controls (£ ) (n=3; results are expressed as percent of controls 
and represent the mean ± SEM; P>0.05). [Ab1-42] = 0.5 mM. 
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  a7 
3.5 Effect of Ab 1-42 on the expression of the a7-nAChR subunit 
 
3.5.1  Immunocytochemical findings 
 
Upon Ab1-42 treatment, most of the a7-nAChR-ir neurons appeared shrunken and their 
dendrites were devoid of immunofluorescence (Fig.21). Some larger positive neurons 
displaying weak and diffuse immunostaining were seen. Their borders were difficult to 
define and they had a tendency to form blebs, as if they were about to dissolve (white 
arrows).   
Fig.21: a7-nAChR subunit immunoreactivity in controls (a) and Ab1-42-treated cultures (b). 
[Ab1-42] = 0.5 mM. Bar: 50 mm. 
 
 
a7-nAChR immunoreactivity was expressed in all MAP2-positive cells after Ab1-42 
treatment. The total number of a7-nAChR-bearing neurons appeared to be unaffected by 
Ab1-42. The larger “blebbing” neurons observed after treatment were also counted and 
were found to represent 8.45 ± 1.16 % of the total cell population (results are expressed 
as mean ± SEM).  
 
 
3.5.2 Quantitative determination  
 
Following incubation with Ab1-42, the amount of a7-nAChR protein was not significantly al-
tered compared to control conditions (Fig.22). Together with the unchanged number of 
a7-nAChR-ir neurons after Ab1-42 treatment, this speaks in favor of unchanged 
concentrations of the receptor protein in individual neurons.  
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Fig.22: Western blot analysis of the a7-nAChR protein. The total amount of protein was not 
significantly reduced after Ab1-42 incubation (¢ ) in comparison to controls (£ ) (n=3; results 
are expressed as percent of controls and represent the mean ± SEM; P>0.05). [Ab1-42] = 0.5 
mM. 
 
The presently used mAb 306, described by Dominguez del Toro et al. (1994), is currently 
undergoing specificity tests in our laboratory. Immunohistochemical assays recently 
performed by our group on brain sections of a7-nAChR knock-out mice raised the 
possibility that mAb 306 could recognize unexpected epitopes in addition to the             
a7-nAChR subunit. All the antibodies most commonly used against the a7-nAChR subunit 
(mAb 319, Sigma; C-20 and H-302, Santa Cruz) were tested by immunochemistry, leading 
to similar results. The same observations were made by another group (Herbert et al., 
2004). In Western blot analysis, the mAb 306 gave only one band at the expected MW. 
2D-electrophoresis will now be performed to investigate further the nature of possibly 
cross-reacting proteins.  
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3.5.3 Receptor binding assay 
 
It has recently been demonstrated that the neuronal nAChRs which bind a-bungarotoxin 
with high affinity (a-BgtRs) and are found throughout the nervous system (Castro and 
Albuquerque, 1995), appear to be composed solely of a7 subunits in rat brain (Drisdel 
and Green, 2000). These receptors can assume two different conformations, which 
correspond to the active and to the inactive binding states, and only those receptors which  
are in the active conformation are able to interact with a-bungarotoxin (a-Bgt) and 
acetylcholine (Rakhilin et al., 1999). Using iodinated a-Bgt for binding assays it is 
therefore possible to implement the data obtained by Western blot analysis on the total 
amount of receptor protein with information about their functionality. 
Cultures were therefore incubated with [125 I]a-Bgt and the receptor affinity and the total 
binding sites determined. The results obtained do not point to a statistically significant 
difference between the Kd values of treated and untreated cultures (P>0.05), showing that 
the affinity of the homomeric a7-nAChRs for [125I]a-Bgt was unaffected by Ab1-42 
incubation (Fig.23). The total number of binding sites (RTOT) remained also unaltered 
(P>0.05) (Figs.23,24).  
                          
                        Scatchard plot                                           Scatchard plot 
                            Control         Ab1-42 
 
 
 
 
 
 
 
 
 
 
          
            Kd   =  1.0 ± 0.15  nM                                      Kd   =  0.99 ± 0.16  nM 
            RTOT = 116.9  ±  21.5 fmol/mg protein             RTOT = 116.8  ±  22.0 fmol/mg protein 
 
Fig.23: Scatchard plot of the data (results are expressed as mean ± SEM). [Ab1-42] = 0.5 mM. 
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Fig.24: Total and non-specific 
binding are represented for 
controls (a) and Ab1-42-treated 
cultures (b). In (c) the specific 
binding in controls and under 
incubation condition is repor-
ted (n=3; results are expressed 
as mean ± SEM). [Ab1-42] = 0.5 
mM. 
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3.6 Effect of Ab 31-34 on cultured neurons   
 
The modification of [Ca2+] homeostasis is thought to be one of the various cytotoxic 
alterations caused by Ab1-42 at the cellular level (Mattson et al., 1993). Laskay et al. (1997) 
described the effect of different amyloidogenic peptides on the long-term elevation of 
intracellular [Ca2+] in primary rat astrocyte cultures. Comparative fluorimetric studies 
showed that Ab1-40,  Ab1-42 and Ab25-35 induce similar effects on the intracellular [Ca
2+], 
suggesting the region 25-35 to be the active center of the peptide. Ab31-34, on the other 
hand, was able to antagonize this effect, raising the possibility that the short peptide may 
be protective towards Ab1-42. In this study, the possible protective action of Ab31-34 against 
some Ab1-42-induced alterations, like the retraction of the dendrites and the shrinkage of 
the cell bobies, was investigated. The impact of Ab31-34 on t-protein phosphorylation state 
was also studied. 
 
3.6.1 Neuron morphology and number 
 
Upon Ab31-34 incubation, MAP2 immunoreactivity revealed alterations of the cytoskeletal 
structure which appeared to be different from those caused by Ab1-42. Many cells exhibited 
a swollen cell body in the region of the apical dendrite and the staining in these parts was 
often weaker (Fig.25a, white arrows). To test the possible protective action of Ab31-34 
against Ab1-42, cultures were treated with both amyloidogenic peptides. As shown in 
Fig.25b, neurons exhibited damages typical for both Ab1-42 (white arrow-heads) and    
Ab31-34 (white arrows), showing the own toxic properties of the shorter peptide . 
 
 
Fig.25: MAP2 immunoreactivity in Ab31-34-treated cells (a). In (b), Ab31-34 and Ab1-42 were used 
simultaneously for the incubation. [Ab1-42] = 0.5 mM; [Ab31-34] = 0.125 mM. Bar: 50mm. 
  (a)   (b) 
Ab31-34 Ab1-42 + Ab31-34  
MAP2 MAP2 
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In the presence of Ab31-34 or Ab31-34 + Ab1-42 the total number of MAP2-positive neurons 
per coverslip was not altered in comparison to controls (Fig.26). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.26: Assessment of the total number of MAP2-positive cells in controls (£ ), Ab31-34- (¢ ) 
and Ab31-34+Ab1-42-treated cultures (¢ ) (n=5; results are expressed as mean ± SEM; P>0.05). 
[Ab1-42] = 0.5 mM; [Ab31-34] = 0.125 mM. 
 
 
 
3.6.2 LDH determination 
 
The cytotoxicity of Ab31-34 was tested measuring the LDH release in the cell supernatant 
after treatment. Upon Ab31-34 incubation, no significant difference in the LDH release was 
found (Fig.27) indicating that the cell viability remained unaltered. The same observation 
on cell viability was made when both peptides were used for the incubation (Fig.27). 
 
     Sample  MAP2-positive cells 
       per coverslip  
      Control       21508  ±  904 
      Ab31-34       20721  ±  710 
Ab31-34 + Ab1-42       21266  ±  949 
                                                                                                                               3. Results 
                                                                      48  
 
 
 
 
 
 
Fig.27: Cytotoxicity in controls (£ ), Ab31-34- (¢) and Ab31-34+Ab1-42-treated cultures (¢ ), 
reported as formazan absorbance (n=4; results are expressed as mean ± SEM; P>0.05). 
[Ab1-42] = 0.5 mM; [Ab31-34] = 0.125 mM. 
 
 
3.6.3 Morphological measurements 
 
The determination of the total MAP2-stained area in the presence of Ab31-34 or Ab31-34 + 
Ab1-42 revealed no significant difference between controls and treated cultures. The 
decrease of the MAP2-ir area measured after Ab1-42 incubation could not be observed 
under these incubation conditions  (Fig.28). 
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Cytotoxicity assay (LDH)
0.00
0.05
0.10
0.15
0.20
0.25
ab
so
rb
an
ce
 (4
90
 n
m
)  
 Control                 Ab 31-34             Ab 31-34 + Ab 1-42
                                                                                                                               3. Results 
                                                                      49  
 
 
 
 
 
 
Fig.28: The MAP2-stained area was measured as percent of the total area on the coverslip in 
controls (£ ), Ab31-34 (¢ ) and Ab31-34+Ab1-42-treated cultures (¢ ) (n=5; results are expressed 
as mean ± SEM; P>0.05). [Ab1-42] = 0.5 mM; [Ab31-34] = 0.125 mM. 
 
 
3.6.4 Quantitative determination of MAP2 isoforms 
 
The effect of Ab31-34 on the expression of the different MAP2 isoforms was investigated by 
means of Western blot. The total amount of MAP2c remained unaffected (Fig.29), as it 
was noticed with Ab1-42. In contrast to the findings obtained upon Ab1-42 treatment, no 
decrease in the total amount of MAP2b was seen under Ab31-34 incubation (Fig.29), 
suggesting a different impact of the smaller peptide on the expression of cytoskeletal 
proteins in comparison to the longer Ab form. 
 
       Sample         Percent 
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        Control        12.7  ±  0.6 
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3.7 Effect of Ab 31-34 on the phosphorylation state of the t-protein 
 
Incubation with the antibodies AT8, AT180, 12E8 and AD2 was performed in order to 
investigate the impact of Ab31-34 on the phosphorylation state of the t-protein in the 
different functional domains. 
       Sample              MAP2c              MAP2b 
        Control                100                 100 
        Ab31-34          92.2 ±  4.2          99.2  ±  4.1 
Fig.29: Western blot analysis 
of the two MAP2 isoforms (a). 
The total amount of MAP2b 
and MAP2c was not reduced 
under Ab1-42 incubation (¢ ) in 
comparison to controls (£ ) (b) 
(n=3; results are expressed as 
percent of controls and repre-
sent the mean ± SEM; P>0.05). 
[Ab31-34] = 0.125 mM. 
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3.7.1 Immunocytochemistry  
 
In the presence of the short amyloid fragment Ab31-34, AT8 and AD2 immunoreactivity 
seemed to be increased when compared to controls (Fig.30). The positive staining 
appeared to be localized particularly in the cell body and in the apical dendrite, where 
cells were swollen. As already mentioned, t-protein is distributed in axons under normal 
conditions (Binder et al., 1985). Its presence in the cell bodies and in the dendrites is a 
consequence of its abnormal phosphorylation state (for reviews see Mandelkow et al., 
1995; Trojanowski and Lee, 1995). AT8, AD2 and 12E8 immunostaining revealed 
positivity in the apical dendrite, which was more intensely stained in comparison to 
untreated cultures, while AT180 labeling was too weak to distinguish the immunoreactivity 
from the background (Fig.30).  
      
 
 
Fig.30: Immunofluorescence labeling of different t -phosphorylation sites using AT8 (a), AD2 
(b), 12E8 (c) and AT180 (d) antibodies in Ab31-34-treated cultures. [Ab31-34] = 0.125 mM. Bar: 50 
mm. 
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*
To extend the reported findings, AT8-, 12E8- and AD2-ir neurons were counted. Upon 
Ab31-34 incubation, a statistically significant increase in the number of AT8- and AD2-ir 
neurons was found in comparison to vehicle-treated cultures, while numbers of 12E8-ir 
cells remained unaltered (Fig.31).  
 
 
 
 
 
 
 
Fig.31: Total number of AT8- (a), AD2- (b, next page) and 12E8-positive cells (c, next page) in 
controls (£ ) and Ab31-34-treated cultures (¢ ) (n=3; results are expressed as mean ± SEM; 
*P<0.05). [Ab31-34] = 0.125 mM. 
 
 
 
 
 
 
 
 
       Sample      AT8-positive cells 
           per coverslip 
        Control           7230 ±  828  
        Ab31-34           9146 ±  728 
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       Sample      AD2-positive cells 
           per coverslip 
        Control           4775 ±  388  
        Ab31-34           5952 ±  608 
       Sample      12E8-positive cells 
           per coverslip 
        Control           7314 ±  700  
        Ab31-34           7802 ±  299 
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3.7.2 Western blot analysis 
 
Quantitative determination of t-protein phosphorylated at the distinct epitopes supported 
the results obtained by immunocytochemistry. In contrast to the observations made after 
Ab1-42-treatment, following incubation with Ab31-34 the level of phosphorylation of fetal t-
protein resulted to be significantly increased at AT8 sites (Fig.32).  
 
 
 
 
 
Fig.32: Total amount of t -protein phosphorylated at AT8 epitopes. Compared to controls 
(£ ), Ab31-34-treated cultures (¢ ) contained a higher amount of phosphorylated t -protein at 
these epitopes (n=5; results are expressed as percent of controls and represent the mean ± 
SEM; *P<0.05). [Ab31-34] = 0.125 mM.  
  
 
In accordance with the increase of t-protein phosphorylated at AT8 sites, the total amount 
of t-protein dephosphorylated at Ser199 / Ser202, detected using the antibody tau-1, was 
significantly reduced under incubation conditions in comparison to vehicle-treated cells 
(Fig.33), in contrast to the Ab1-42-incubation (see 3.4.2). 
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Fig.33: The total amount of t -protein dephosphorylated at tau-1 epitopes was significantly 
decreased in Ab31-34-treated cultures (¢ ) in comparison to controls (£ ), as revealed by 
densitometric analysis of Western blot bands (n=5; results are expressed as percent of 
controls and represent the mean ± SEM; *P<0.05). [Ab31-34] = 0.125 mM. 
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Results obtained when the AD2 antibody was used to detect t-phosphorylation at Ser396 
and Ser404 also indicated an increase in the phosphorylation state. In the presence of the 
short Ab fragment, the amount of phosphorylated t-protein at these epitopes was 
significantly increased (Fig.34). 
 
 
 
 
 
 
Fig.34: The total amount of t -protein phosphorylated at AD2 epitopes was significantly 
higher in Ab31-34-treated cultures (¢ ) than in controls (£ ) (n=3; results are expressed as 
percent of controls and represent the mean ± SEM; *P<0.05). [Ab31-34] = 0.125 mM. 
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In contrast to the effect observed at AT8 and AD2 sites, no significant difference in the 
amount of phosphorylated t-protein at AT180 (Fig.35) and 12E8 epitopes (Fig.36) was 
found between vehicle- and Ab31-34-treated cells. 
 
 
 
 
 
 
Fig.35: Western blot analysis of t -protein phosphorylated at AT180 epitopes did not show 
any significant difference in the total amount of protein in controls (£ ) and Ab31-34-treated 
cultures (¢ ) (n=6; protein amounts are expressed as percent of controls and represent the 
mean ± SEM; P>0.05). [Ab31-34] = 0.125 mM. 
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Fig.36: Western blot analysis of t-protein phosphorylated at 12E8 epitopes. No significant 
change in the total amount of protein in controls (£ ) and Ab31-34-treated cultures (¢ ) was 
found (n=3; protein amounts are expressed as percent of controls and represent the mean ± 
SEM; P>0.05). [Ab31-34] = 0.125 mM. 
 
 
3.8 Effect of Ab 31-34 on the expression of the a7-nAChR subunit 
 
3.8.1 Immunocytochemical findings 
 
a7-nAChR immunostaining following Ab31-34 treatment (Fig.37) showed a more conserved 
cell morphology in comparison to Ab1-42-treated cultures, indicating a probably minor effect 
of the shorter peptide on the a7-nAChR subunit. As previously reported, all MAP2-positive 
neurons express the a7-nAChR subunit, and their number, like the number of MAP2 cells, 
was therefore not affected by the presence of Ab31-34. 
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                       Fig.37: a7-nAChR subunit immunoreactivity in Ab31-34-treated cells.  
                     [Ab31-34] = 0.125 mM. Bar: 50 mm. 
 
 
3.8.2 Quantitative determination  
        
The total amount of a7-nAChR protein did not change significantly under Ab31-34 
incubation in comparison to vehicle-treated cultures (Fig.38).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.38: Western blot analysis of the a7-nAChR protein. Its total amount was not significantly 
changed after Ab31-34 treatment (¢ ) compared to controls (£ ) (n=3; results are expressed as 
percent of controls and represent the mean ± SEM; P>0.05). [Ab31-34] = 0.125 mM. 
       Sample         a7-nAChR 
        Control                100 
        Ab31-34         91.2  ±  7.6 
  a7 
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3.8.3 Receptor binding assay 
 
The binding assay performed after Ab31-34 treatment did not reveal any significant 
difference in the affinity of the homomeric a7-nAChRs for [125I]a-Bgt. The value of Kd 
(Fig.39a) remained in fact in the same range as measured in controls (see 3.5.3) and was 
not significantly different (P>0.05). The total number of binding sites (RTOT) was also not 
affected by the incubation (P>0.05) (Fig.39). 
 
       (a)               Scatchard plot                                         
                                 Ab31-34 
 
 
 
 
 
 
 
 
 
            Kd   =  0.78 ± 0.04  nM                                    
            Rtot = 118.9  ±  32.0 fmol/mg protein     
 
 
       (b)        [125I]a -Bgt Binding assay            (c)        [125I]a -Bgt Specific binding 
                                 Ab31.34                                                            Ab31.34 
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  (a)    (b) 
  (c)   (d) 
3.9 Colocalization of the a7-nAChR subunit with hyperphosphorylated t-protein 
 
Immunocytochemical assays were performed to check whether the localization of the a7-
nAChR subunit was influenced by the Ab31-34-induced t-hyperphosphorylation. a7-nAChR 
subunit immunoreactivity was detected in all AT8- and AD2-positive neurons (Fig.40). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.40: The immmunolabeling of the a7-nAChR subunit (b,d) was not influenced by the 
presence of  t -protein phosphorylated at AT8 (a) and AD2 epitopes (c). [Ab31-34] = 0.125 mM. 
Bar: 50 mm. 
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3.10 Summary of results 
  
The effects of the two peptides are schematically represented here.  
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Results: appendix  
 
a4-nAChR subunit  
 
Immunocytochemical studies were performed using the anti-a4-nAChR subunit antibody 
from Chemicon (Fig.41).  
Fig.41: a4-nAChR subunit immunoreactivity (a) and correspondent MAP2 staining (b) in 
untreated cultures. Bar: 50 mm. 
 
The a4-nAChR subunit immunoreactivity appeared to be homogeneously distributed on 
the cell surface. It was present in all MAP2-positive cells, as revealed by neuron counting. 
However, the following Western blot analysis, for which the antibody has not been tested 
by the manufacturer, cast doubt on the specificity of the antibody. For the rat a4-nAChR 
subunit, a 74 kD band was expected. Instead, two other bands at about 30 and 90 kD, 
respectively, were found (Fig.42). 
The investigation of the a4-nAChR subunit was therefore not continued.    
  control 
  MAP2       (b)  
 
 
control 
a4         (a) 
Fig.42: Western blot ana-
lysis of the a4-nAChR sub-
unit. Two main bands were 
obtained at 30 and 90 kD 
using different concentra-
tions of antibody.  
(a)=1:1000 
(b)=1:2000 
(c)=1:5000  
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4. DISCUSSION 
 
In Alzheimer’s disease, the possible mechanisms linking Ab deposition, cytoskeletal 
damage, t-protein hyperphosphorylation and nAChR expression still need to be clarified. 
The aim of the present study was the evaluation of the neurotoxic effects of the Ab 
fragment Ab1-42 and the putatively protective fragment Ab31-34 on the cytoskeletal proteins 
of cultured rat hippocampal neurons, more precisely on MAP2 expression and on the 
phosphorylation state of the t-protein. A second point of interest was the attempt to 
determine expression and distribution of some nAChR subunits in the same model, and 
their possible alterations after treatment with the two amyloidogenic peptides.  
 
 
4.1  Effects of Ab 1-42  
 
Soon after the neurotoxic potency of amyloid peptides had been corroborated (Yankner et 
al., 1990; Pike et al., 1991a, 1991b) attempts have been made to elucidate the possible 
molecular mechanisms leading to neuronal dystrophy in Ab-exposed cultured hippo-
campal neurons. In this vein, different Ab fragments have been employed for the 
incubation. In  this study, the first amyloidogenic peptide used for the treatment was fibrillar 
Ab1-42. This Ab  fragment was chosen for the following reasons. (1) Together with Ab1-40, 
Ab1-42 in fact is one of the two products generated in vivo by the b- and g-secretase APP-
cleavage (for review see Mattson, 1997). (2) Methodological studies concerned with the 
physicochemical nature of Ab peptides and their biological effects when used for in vitro 
approaches (Busciglio et al., 1992; Lorenzo and Yankner, 1994) showed that there is a 
correlation between the toxicity and the aggregation state of the peptide, and that the 
reported neurotoxic effects, like retraction of neurites, dystrophic changes and decreased 
density of the presynaptic terminals along the dendrites, can only be expected from 
incubation with fibrillar Ab. The longer and more hydrophobic forms of Ab  aggregate more 
rapidly: self-association has in fact been reported to occur faster for Ab1-42 than for the 
shorter form Ab1-40 (Snyder et al., 1994). The usual technique to obtain amyloid fibrils is 
the pre-aging of an aqueous 350 mM stock solution for at least 4 days at 37°C, from which 
the actual incubation solutions are prepared (Lorenzo and Yankner, 1994). This is exactly 
how we prepared our solutions (cf. 2.5.5). The formation of fibrils was confirmed by 
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electron microscopy. Although Ab1-42 toxicity is comparable in aqueous solution, 
acetonitrile and DMSO (Busciglio et al., 1992), an aqueous solution was preferred to 
exclude any possible toxic role of the solvent. (3) Ab1-42 is more abundant in AD brains in 
comparison to non-diseased ones and cell transfection experiments have shown that 
mutations of APP and presenilin, which can cause AD, and other risk factors (Apo E 
alleles) lead to Ab1-42 production and accumulation (Schmechel et al., 1993; Suzuki et al., 
1994; Scheuner et al., 1996). (4) Relevant for the choice of Ab1-42 were also observations 
indicating strong similarities between neurite dystrophy in AD and Ab1-42-induced neurite 
dystrophy in hippocampal neuronal cultures (Pike et al., 1992). 
Cells were incubated after seven days in culture, as the neuronal differentiation normally 
occurs within five days (Busciglio et al., 1995). A three-day Ab1-42 treatment allowed the 
appreciation of morphological changes without leading to neuron death. The last point 
was taken into consideration also when deciding the appropriate concentration of Ab1-42, 
as concentrations higher than 2.5 mM have shown to cause cell death (Pike et al., 1991b). 
In the present study, a concentration of 0.5 mM was used. Gravina et al. (1995) have 
shown that Ab1-42, the major peptide fragment of amyloid plaques in full-blown Alzheimer’s 
disease, is present in concentrations of about 3000 to 5000 pmol/g w.w. in Alzheimer 
brains. Similar ranges have been demonstrated in plaque-forming mouse strains like the 
Tg2576 mouse (Kawarabayashi et al., 2001). Wiebringhaus et al. (2000) reported 
concentrations of 2.3 pmol/g w.w. of Ab1-42 in the brains of APP SL x PS1mut mice. Taken 
together, these data suggest that concentrations of Ab1-42 in the end-stage of Alzheimer’s 
disease amount to maximally 5 mM while those reflecting the development of amyloid 
plaque formation, e.g. in the APP SL x PS1mut mice, range from low initial values to 
maxima of 2 nM concentrations at the age of 16 months. The presently used 
concentration of 0.5 mM thus represents a concentration that ranges between the level 
that is probably necessary to induce plaque formation in mouse mutants and the ones 
seen in full-blown Alzheimer’s disease.  
 
 
4.1.1 Cell morphology 
 
Looking at the impact of Ab1-42 on cell morphology, retraction of the dendrites and 
shrinkage of the cell bodies were evident after the current treatment, and the 
quantification of these alterations resulted to be significant, as shown by stereological 
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measurements of the total MAP2-positive area on the coverslip. These observations are 
consistent with previous studies on hippocampal primary cultures treated with fibrillary Ab, 
which reported similar findings (Yankner et al., 1990; Pike et al., 1992; Lorenzo and 
Yankner, 1994). In contrast to those studies, where a 20 mM concentration caused a 
massive cell death, the observed effect on cell morphology with Ab1-42 in the currently 
used 0.5 mM concentration was not accompanied by any significant impact either on the 
total number of neurons or on the number of lysed cells. The only alteration which occured 
at the cytoskeletal level in the presence of Ab1-42 was a reduction in the total amount of 
MAP2b. MAP2b is normally expressed pre- and postnatally in rat brain (for review see 
Goedert et al., 1991) and its level remains fairly constant during brain development. As it 
is generally accepted that MAP2b is required for neurite outgrowth (for review see Shafit-
Zagardo and Kalcheva, 1998), a decrease in its expression may play a role in the 
observed retraction of dendrites. 
 
 
4.1.2 Phosphorylation state of the t-protein 
 
Besides the investigation of Ab effects on cell morphology, its potential impact on the 
hyperphosphorylation of the t-protein became of particular interest. Takashima et al. 
(1993) were able to show an increase in the activity of t-protein protein kinase / glycogen 
synthase kinase 3 (TPK1/GSK-3b), one of the most important enzymes involved in t-
hyperphosphorylation, after a 24-hour incubation with 20 mM Ab1-43. They also detected 
immunoreactivity using the “Alz-50” antibody under incubation conditions. This antibody, 
although it is not specific for phosphorylated derivates of the t-protein, recognizes a t-
epitope associated with PHFs in AD brains (Wolozin et al., 1986). Busciglio et al. (1995), 
using rat and human cortical dissociation cultures, investigated the phosphorylation state 
of the t-protein upon a seven-day exposure to 20 mM Ab1-40. They could show that this 
kind of treatment resulted in a distinct phosphorylation of the t-protein at Ser-202 
(antibody AT8) and at Ser-396 / Ser-404 (antibody PHF) which was reversible after 
induction of dephosphorylating conditions. Götz et al. (2001) reported that the injection of 
Ab1-42 fibrils in the brain of P301L mutant human t transgenic mice can significantly 
accelerate NFT formation in the cell bodies within the amygdala. However, neither the 
mutation nor Ab1-42 injection alone were sufficient to generate high numbers of NFTs. In 
this study, a 0.5 mM concentration of Ab1-42 did not lead to a statistically significant 
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increase in t-phosphorylation at Ser-202 (antibody AT8) or Ser-396 / Ser-404 (antibody 
AD2) after three days of exposure. The same result was obtained at the phospho-epitopes 
Thr-231 / Ser-235 (antibody AT180) and Ser-262 (antibody 12E8). These findings suggest 
that Ab1-42, at these concentrations, does not lead to t-hyperphosphorylation, and that t-
hyperphosphorylation is consequently not involved in the morphological alterations 
observed after Ab1-42 incubation. The major Ab fragment used by Busciglio et al. (1995) 
was Ab1-40, but they also reported the use of Ab1-42. As mentioned above, previous studies 
had mostly used concentrations in the range of 15-25 mM (Pike et al., 1991, 1992; 
Busciglio et al., 1995; Grace et al., 2003). These concentrations are far beyond the 
highest values assessed in human AD brain as well as in transgenic mice and have been 
applied for quite long incubation times. Moreover, we observed that a 0.5 mM 
concentration of Ab1-42 was sufficient to induce morphological changes in treated neurons 
after a three-day incubation.  
Assessment of phosphorylation sites was presently performed with standard 
immunochemical procedures: for the immunocytochemical demonstration well-established 
immunoperoxidase and immunofluorescent techniques were used. The same holds true 
for the Western blot techniques. The only relevant difference between the conditions used 
in this study and those employed by others (Takashima et al., 1993; Busciglio et al., 1995) 
appears therefore to be the amyloid peptide concentration. It may be that the massive 
effect on t-protein phosphorylation sites described in those studies is related to the use of 
rather high concentrations of Ab  which are unlikely to occur even in full-blown AD (cf. 
Gravina et al., 1995).  
The present results do not exclude an interplay between amyloid and t-hyperphos-
phorylation in AD, but suggest that the formation of more complex structures, like amyloid 
plaques, may be required. In the initial phases of the disease, with Ab1-42 levels still being 
low, the peptide most likely induces morphological alterations in exposed neurons which, 
however, seem to be connected with changes in MAP2 metabolism but not with the 
phosphorylation status of the t-protein. Whether the currently observed alterations in 
MAP2 expression may be related to an impact on the t-protein which is not accompanied 
by its hyperphosphorylation will have to be elucidated in the future. 
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4.1.3 a7-nAChRs 
 
Immunocytochemical staining of the cultures was performed with antibodies directed 
against the a7-nAChR subunit. Following Ab1-42 treatment, nAChR-immunoreactive 
neurons exhibited an altered cell morphology in comparison with untreated cultures: 
neurons were shrunken and showed a tendency to form blebs to different extent or even 
displayed signs of dissolution.  
No difference in the total number of a7-nAChR-positive cells was found. To the best of our 
knowledge this is the first in vitro study concerned with the effects of Ab1-42 on nAChR 
expression in primary neuronal cell cultures. Previous studies on AChRs performed on 
human brains showed that a7-immunoreactive neurons were detected in all cortical layers 
in non-diseased subjects, matching the pattern of their mRNA transcript distribution, which 
also holds true for the rat brain (Luetje et al., 1990). In AD patients, by contrast, a loss of 
immunoreactive neurons occurred, especially in the upper cortical layers, where most of 
them were only weakly stained (Wevers et al., 2000).  
In the present study, quantitative determination of the a7-nAChR subunit by means of 
Western blot revealed no change in its expression under incubation conditions in 
comparison to untreated cultures. In contrast to our findings, Guan et al. (2001) found a 
reduction in the a7-nAChR subunit expression and in the correspondent mRNA transcript 
in PC12 cells after incubation with non-fibrillar Ab1-40. The incubation with a diverse 
peptide, its different aggregation state and the choice of a different cell model could 
explain the different results obtained. In AD patients, Guan et al. (2000) found the a7-
nAChR subunit expression not to be affected in the cerebral cortex, while Burghaus et al. 
(2000) reported a significant reduction in the same brain area. In the hippocampus, the 
total amount of a7-nAChR protein was shown to be decreased (Guan et al., 2000). No 
difference either in the cortical distribution pattern of a7-nAChR subunit mRNA-expressing 
neurons or in their density was found in the frontal cortex (Wevers et al., 2000). The 
reduction in the expression of receptor protein in AD brains could be region-specific and 
reflect the severity of the disease (for review see Bourin et al., 2003), and the conditions 
leading to the possible damage therefore difficult to reproduce in cell culture. 
The binding assay performed with [125I]a-Bgt to test the functional state of the homomeric 
a7-nAChRs in our cultures resulted in no change in the total number of binding sites after 
Ab1-42 treatment. In PC12 cells, incubation with non-fibrillar Ab1-40 led to a decrease in the 
number of binding sites in comparison to untreated cultures (Guan et al., 2001). In 
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contrast to those findings, Dineley et. al. (2002) reported that the incubation of a7-nAChR 
subunit-transfected cells with non-fibrillar Ab1-42 leads to receptor activation. It seems that 
the outcome of the different experiments is strongly influenced by the individual model 
used and by the form of amyloid employed. In AD brains, some groups found no 
difference in the total amount of binding sites (Perry et al., 2000), while others detected a 
region-specific loss (Hellstrom-Lindahl et al., 1999), thus supporting the hypothesis of a 
possible relation between localization of the damage and severity of the pathology (for 
review see Bourin et al., 2003). 
It has been recently demonstrated that Ab1-42 can bind the a7-nAChR with very high 
affinity (Wang et al., 2000) and that it tends to accumulate in a7-nAChR rich cells (Nagele 
et al., 2002). However, nothing is known about the underlying mechanism and the site of 
interaction. In the present study, no effect on the affinity of homomeric a7-nAChRs for 
[125I]a-Bgt was found after Ab1-42 incubation. Our results do not exclude that Ab1-42 could 
interact with the receptor, but suggest that possible interactions do not influence the a-Bgt 
binding site. It could be speculated that the capability of the homomeric a7-nAChRs to 
bind ACh remains also unaffected, as it was demonstrated that the receptors which are 
able to bind a-Bgt are in the active conformation and can also bind ACh (Rakhilin et al., 
1999). 
 
 
4.2 Effects of Ab 31-34  
 
The second amyloidogenic peptide used in this study was the shorter fragment Ab31-34. 
Previous studies reported a protective action of this shorter form against Ab1-42 effects. 
Ab31-34 was shown to antagonize the Ab1-42-induced elevation of intracellular [Ca2+] in 
primary cultures of rat astrocytes (Laskay et al., 1997), and to abolish the elevation of 
extracellular glutamate and aspartate concentrations caused by Ab1-42 on cholinergic 
neurons of the rat basal nucleus of Meynert in vivo (Harkany et al., 1999). The shorter 
fragment could also attenuate the Ab1-42-induced behavioral dysfunctions (markedly 
reduced horizontal motor activities) in rats. An updated search for sequence similarities 
revealed that the amino acid sequence Ile-Ile-Gly-Leu is present in about 250 human 
proteins. It appears, however, difficult to find a relation between the functions of these 
peptides and the effects caused by the tetrapeptide. Yankner et al. (1990) were able to 
show that the highly hydrophobic sequence Ile-Ile-Gly-Leu is contained in a number of 
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peptides belonging to the tachykinin family. It is noteworthy, however, that only the 
application of tachykinin antagonists and not of agonists led to neurotoxic effects 
comparable to those obtained with Ab.  Ab31-34 was presently employed to investigate 
further its possible role as a neuroprotective agent.  
In the above mentioned studies, Ab31-34 and Ab1-42 were used in equimolar concentrations. 
In this work, a concentration of 0.125 mM was chosen for the Ab31-34 incubation because it 
represented the highest concentration not affecting the cell viability. The LDH cytotoxicity 
assay revealed in fact no impact of 0.125 mM Ab31-34 on cell survival and on the total 
number of neurons. The other incubation conditions were the same as for Ab1-42. 
 
 
4.2.1 Cell morphology 
 
As regards the morphological aspects, Ab31-34 led to alterations in the region of the apical 
dendrite, which resulted to be swollen. These alterations apparently do not involve MAP2b 
or MAP2c expression, as their level remained unaffected. In the presence of both 
peptides, neurons exhibited the reported morphological changes caused by Ab31-34, i.e the 
swollen cell body in the region of the apical dendrite, together with the Ab1-42-induced 
retraction of dendrites. With both peptides, however, the total MAP2-stained area was not 
significantly decreased. Looking at these findings, it can be concluded that Ab31-34 
prevents to some extent the alterations caused by Ab1-42, but it can not be considered 
protective for the cell morphology, as it showed own toxic effects.  
 
 
4.2.2 Phosphorylation state of the t-protein 
 
In contrast to Ab1-42, the shorter fragment Ab31-34 was able to cause a massive hyperphos-
phorylation of the t-protein at Ser-202 (AT8) and at Ser-396 / Ser-404 (AD2), while no 
increase in the phosphorylation levels at Ser-262 (12E8) and Ser-231 / Ser-235  (AT180) 
was found.    
The observed hyperphosphorylation of the t-protein at AD2 sites is of main importance, 
as it concerns epitopes possibly involved in the formation of paired helical filaments. The 
microtubule binding capability of the t-protein is necessary for the maintenance of t 
functions in the stabilization of microtubules. It has been reported that the detachment of 
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the protein from the microtubular structure occurs only when the hyperphosphorylation 
takes place at Ser-262 or Ser-214 (for review see Mandelkow and Mandelkow, 1998). t-
protein microtubule binding is therefore most likely not directly affected by the Ab31-34-
induced hyperphosphorylation. On the other hand, even if the hyperphosphorylation at 
Ser-262 dramatically reduces the affinity of t-protein for microtubules, this alteration alone 
is not sufficient to provoke the loss of binding, which is strongly influenced by hyper-
phosphorylation at sites located outside the microtubule binding domain (for review see 
Buèe et al., 2000). It can therefore not be excluded that the hyperphosphorylation at AD2 
sites might play a role in the detachment of the t-protein, which in AD could account for 
the microtubule disappearance, breakdown of the cellular trafficking and subsequent 
death of neurons (for review see Mandelkow and Mandelkow, 1998). 
Ab31-34 is a synthetic peptide which does not occur in vivo. Its capability to induce t-
hyperphosphorylation at some epitopes could however be used to obtain an in vitro model 
in which different cellular aspects (e.g. protein expression or receptor functionality) can be 
studied under hyperphosphorylating conditions. This model would thus allow to investigate 
possible correlations between hyperphosphorylated t-protein and alterations in cellular 
pathways of interest. 
 
 
4.2.3 nAChRs 
 
Ab31-34 did not produce any morphological alteration in cells stained with the anti-a7-
nAChR subunit antibody. As with Ab1-42, the number of a7-nAChR subunit-expressing 
neurons was not altered and the level of a7-nAChR subunit expression maintained when 
comparing vehicle-treated cultures with those exposed to the tetrapeptide Ab31-34. The 
treatment did not affect either the affinity of the homomeric a7-nAChRs for [125I]a-Bgt or 
their total number. 
 
 
4.2.4 Possible mechanisms of action of Ab31-34. 
 
Studies concerned with the design of potential anti-Ab drugs suggest that synthetic 
amyloidogenic peptides could antagonize the recognition and surface binding of Ab 
(Cowburn et al., 1997). Another line of evidence attributes to the synthetic short 
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amyloidogenic peptides the capability of acting as b-sheet breakers and avoiding in this 
way the formation of amyloid fibrils (Soto et al., 1998, 2000). Looking at the results 
obtained in this study, it appears difficult, however, even to speculate about the 
mechanism of action of Ab31-34.  
 
 
4.3 Colocalization of the a7-nAChR subunit with hyperphosphorylated t-protein 
 
Colocalization studies showed that the a7-nAChR subunit was not affected by the 
presence of hyperphosphorylated t-protein at AT8 and AD2 epitopes. Upon Ab31-34 
incubation, which has been demonstrated to increase the level of phosphorylation at these 
sites, the expression pattern of the a7-nAChR subunit remained unaltered.  
When looking for the colocalization of nAChR neurons with NFT-bearing neurons in 
autopsy samples, it turned out that almost none of these neurons simultaneously 
displayed nAChR- and NFT-immunoreactivity (Wevers et al., 1999). This led us to the 
idea that hyperphosphorylated t-protein or NFTs may interfere with nAChR expression    
in vivo. Given the only slight, although significant, decrease of total a7-nAChR amount in 
AD patients, this finding may appear of minor relevance at first sight. It has to be kept in 
mind, however, that the loss of receptors can be region specific (Hellstrom-Lindahl et al., 
1999) and that strategically important neurons - e.g. in the entorhinal cortex  - are prone to 
develop NFTs and lose their receptor equipment (Wevers et al., 1999). 
As shown presently, however, the Ab31-34-induced t-phosphorylation is not a sufficient 
prerequisite for a reduced nAChR expression. The latter may rather be a function of NFT 
formation. So far, no in vitro model is available in which tangle-like structures could be 
elicited by hyperphosphorylation. Tackling this problem will probably require the in vitro 
use of neurons derived from transgenic tangle-forming mice.  
 
 
4.4 Conclusions  
 
It could be presently shown that Ab1-42, in concentrations most likely occuring during the 
development of amyloid plaques in AD (cf. data on human AD brain and transgenic mice 
as reported in 4.1) does not lead to an increase in t-phosphorylation at the AD relevant 
sites Ser-202 and Ser-396 / Ser-404 in cultured hippocampal neurons. This finding is 
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accompanied by a lack of changes in the expression of the a7-nAChR subunit, in the 
affinity of the homomeric a7-nAChRs for [125I]a-Bgt and in their total number. 
Data obtained from transgenic mice do not provide an unequivocal answer to the problem 
of t-hyperphosphorylation. On one hand, plaque-forming strains have never been shown 
to develop NFTs. On the other hand, the P301L mouse (Götz et al., 2001) is known to 
develop a high number of NFTs in the amygdala upon Ab injection into the ipsilateral 
hippocampus.  
Ab31-34, by contrast, induces a massive increase in t-phosphorylation at Ser-202 or Ser-
396 / Ser-404. However, there was no change in the expression of the a7-nAChR subunit, 
which was still present in neurons that expressed AT8 and AD2 immunoreactivity upon 
Ab31-34 treatment. This is in contrast with the finding that in human AD brains a 
colocalization of nAChRs and NFT is hardly ever encountered (Wevers et al., 1999; 
Wevers et al., 2001). Experiments performed over defined time courses in humans as well 
as in the mouse mutants will be helpful to get more insight into these phenomena. 
 
The “amyloid cascade” hypothesis, proposed for the first time about a decade ago (Hardy 
and Higgins, 1992), remains a central point in the investigation of the AD 
neurodegeneration. The recent generation of various transgenic mice carrying single or 
double APP, PS and t-protein mutations represents a useful tool for the elucidation of 
possible mechanisms linking Ab, t-hyperphosphorylation and cognitive deficit (for review 
see Sommer, 2002), as shown by different studies (Götz et al., 2001; Lewis et al., 2001). 
It is, however, tempting to speculate that the formation of NFTs and the reduced 
expression of nAChRs in AD brain may be the endpoint of a rather long development 
starting with the induction of t-hyperphosphorylation. The present findings do not exclude 
an active involvement of Ab in these long-lasting processes, but raise some doubts about 
the role of Ab1-42 fibrils as a direct trigger of t-hyperphosphorylation. 
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5. ZUSAMMENFASSUNG 
 
Kennzeichen der Alzheimerschen Erkrankung sind die abnormale Ablagerung von 
Proteinen wie b-Amyloid und hyperphosphoryliertem t-Protein, Veränderungen des 
Zytoskeletts und Störungen der cholinergen Transmission. Mögliche Zusammenhänge 
zwischen b-Amyloid-Ablagerung, t-Hyperphosphorylierung und Expression der 
nicotinischen Acetylcholinrezeptoren wurden durch Inkubation neuronaler Dissoziations-
kulturen aus den Hippocampi embryonaler Ratten mit amyloidogenen Peptiden 
untersucht. Für die Inkubation wurden das b-Amyloid-Fragment mit der höchsten Tendenz 
zu Fibrillenbildung, Ab1-42, und das kürzere, putativ protektive Fragment, Ab31-34, 
eingesetzt. Ab1-42 verursachte eine Retraktion der Dendriten und das Schrumpfen der 
Zellkörper. Weder die Zahl der Neuronen noch die Gesamtzahl lysierter Zellen wurde 
beeinflusst. Eine reduzierte Expression von MAP2b war die einzig beobachtete 
Veränderung. Es wurde keine statistisch signifikante Erhöhung der Phosphorylierungsrate 
der Epitope Ser-202 (Antikörper AT8), Thr-231 / Ser-235 (Antikörper AT180), Ser-262 
(Antikörper 12E8) oder Ser-396 / Ser-404 (Antikörper AD2) des t-Proteins beobachtet. 
Die Gesamtzahl der a7-homomeren Rezeptoren und ihre Affinität für [125I]a-Bgt blieben 
unverändert. 
Die Inkubation mit Ab31-34 führte hingegen zu anderen morphologischen Veränderungen, 
wie dem Anschwellen des apikalen Dendriten. Die von Ab31-34 hervorgerufenen 
Veränderungen betrafen nicht MAP2, die Expression aller MAP2-Proteinkomponenten 
blieb unbeeinflusst. Im Gegensatz zu Ab1-42 verursachte das kürzere Fragment eine 
massive Hyperphosphorylierung des t-Proteins an den Aminosäuren Ser-202 (AT8) und 
Ser-396 / Ser-404 (AD2), jedoch konnte keine Erhöhung der Phosphorylierung an Thr-231 
/ Ser-235 (AT180) oder Ser-262 (12E8) festgestellt werden. Weiterhin beeinflusste Ab31-34 
weder die Anzahl der a7-nAChR-exprimierenden Neurone noch die Expression des 
Proteins der Untereinheit selbst. Es konnte kein Unterschied in der Anzahl der              
a7-homomeren Rezeptoren und in ihrer Affinität für [125I]a-Bgt bestimmt werden. Die    
a7-nAChR-Untereinheit zeigte Kolokalisation mit dem hyperphosphorylierten t-Protein in 
allen AT8- und AD2-positiven Neuronen.  
Zusammengefasst zeigen die vorliegenden Ergebnisse toxische Einflüsse von Ab1-42 auf 
das Zytoskelett bei Konzentrationen, die üblicherweise in Gehirnen von Alzheimer-
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patienten zu finden sind. Gleichzeitig bestehen aber noch einige Zweifel über die Rolle 
der Ab1-42-Fibrillen als direkte Auslöser der t-Hyperphosphorylierung. Was Ab31-34 betrifft, 
so kann es in Bezug auf die Zellmorphologie trotz seiner offensichtlich positiven Wirkung 
auf die Ab1-42-induzierte Dendritenretraktion nicht als protektiv angesehen werden, da es 
eigene toxische Eigenschaften besitzt. 
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